Document:

Exhibit
10.1

 

PRINCIPAL
ACCOUNTING OFFICER EMPLOYMENT AGREEMENT

for

Krista
Fogarty

 

This
Employment Agreement (the “Agreement”), made between Lipocine Inc. (the “Company”) and Krista Fogarty
(“Principal Accounting Officer”) (each a “Party” and collectively, the “Parties”),
is effective as of March 7, 2022.

 

WHEREAS,
the Company desires for Principal Accounting Officer to provide services to the Company;

 

WHEREAS,
Principal Accounting Officer is willing to perform services for the Company on the terms and conditions set forth in this Agreement;

 

NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

 

1.
Employment by the Company.

 

1.1.
Position. Principal Accounting Officer shall serve as the Company’s Principal Accounting Officer, Corporate Controller. During
the term of Principal Accounting Officer’s employment with the Company, Principal Accounting Officer will devote substantially
all of Principal Accounting Officer’s business time and attention to the business of the Company, except for approved vacation
periods and reasonable periods of illness or other incapacities permitted by the Company’s general employment policies.

 

1.2.
Duties and Location.

 

(i)
Principal Accounting Officer shall perform such duties as are required by the Company’s Chief Executive Officer, to whom the
Principal Accounting Officer will report. Principal Accounting Officer’s primary office location shall be the Company’s offices
located in Salt Lake City, Utah. The Company reserves the right to reasonably require the Principal Accounting Officer to perform Principal
Accounting Officer’s duties at places other than Principal Accounting Officer’s primary office location from time to time.

 

1.3.
Policies and Procedures. The employment relationship between the Parties shall be governed by the general employment policies and
practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company’s general
employment policies or practices, this Agreement shall control.

 

    	 

    	 

    

 

2.
Compensation.

 

2.1.
Salary.

 

(i)
For services to be rendered hereunder, the Principal Accounting Officer shall initially receive a base salary at the rate of Two
Hundred Thirty Five Thousand Dollars ($235,000) per year (the “Base Salary”), subject to standard payroll deductions
and withholdings payable in accordance with the Company’s regular payroll schedule.

 

2.2.
Bonus. The Principal Accounting Officer will be eligible for an annual discretionary bonus (“Annual Bonus”) of
up to Twenty-Five percent (25%) of the Principal Accounting Officer’s applicable Base Salary or such higher amount as may be determined
by the Company’s Board of Directors (“Board”) (or compensation committee thereof) from time to time. Whether
the Principal Accounting Officer receives an annual bonus, and the amount of any such annual bonus, will be determined by the Board in
its sole discretion based upon the Company’s and the Principal Accounting Officer’s achievement of objectives and milestones
to be determined on an annual basis by the Board. Bonuses are generally paid by March 15 following the applicable bonus year, and the
Principal Accounting Officer must be an active employee on the date any Annual Bonus is paid in order to earn any such Annual Bonus.
The Principal Accounting Officer will not be eligible for, and will not earn, any Annual Bonus (including a prorated bonus) if the Principal
Accounting Officer employment terminates for any reason before the date Annual Bonuses are paid.

 

2.3.
Standard Company Benefits. The Principal Accounting Officer shall be entitled to participate in all employee benefit programs for
which the Principal Accounting Officer is eligible under the terms and conditions of the benefit plans that may be in effect from time
to time and provided by the Company to its employees. The Company reserves the right to cancel or change the benefit plans or programs
it offers to its employees at any time.

 

2.4.
Expenses. The Company will reimburse the Principal Accounting Officer for reasonable business travel, entertainment or other expenses,
including cellular phone, incurred by the Principal Accounting Officer in furtherance or in connection with the performance of Principal
Accounting Officer’s duties hereunder, in accordance with the Company’s expense reimbursement policy as in effect from time
to time.

 

3.
Termination of Employment; Severance.

 

3.1.
At-Will Employment. Principal Accounting Officer’s employment relationship is at-will. Either Principal Accounting Officer
or the Company may terminate the employment relationship at any time, with or without Cause or advance notice. Upon termination for any
reason, Principal Accounting Officer shall receive (i) all unpaid salary and unpaid vacation accrued through the separation date; (ii)
any payments/benefits to which the Principal Accounting Officer is entitled under the express terms of any applicable Company employee
benefit plan; and (iii) any unreimbursed valid business expenses for which the Principal Accounting Officer has submitted properly documented
reimbursement requests. The Principal Accounting Officer’s right to payment under any then outstanding equity awards shall be governed
by their applicable terms.

 

    	2

    	 

    

 

3.2.
Termination Without Cause; Resignation for Good Reason.

 

(i)
The Company may terminate Principal Accounting Officer’s employment with the Company at any time without Cause (as defined
below). Further, Principal Accounting Officer may resign at any time for Good Reason (as defined below).

 

(ii)
In the event Principal Accounting Officer’s employment with the Company is terminated by the Company without Cause, or Principal
Accounting Officer resigns for Good Reason, then provided such termination constitutes a “separation from service” (as defined
under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from Service”),
and provided that Principal Accounting Officer remains in compliance with the terms of this Agreement and the Company’s policies
applicable to Principal Accounting Officer and satisfies the requirements set forth in Section 4, then Principal Accounting Officer shall
receive the following severance benefits:

 

(a)
Severance (the “Severance”) in an amount equal to twenty-six weeks of Base Salary as in effect immediately prior
to the separation date. The Severance shall be subject to standard payroll deductions and withholdings, and will be payable in a lump-sum
on the 60th day following Principal Accounting Officer’s Separation from Service.

 

(b)
Six months accelerated vesting of all of Principal Accounting Officer’s equity interests in the Company.

 

(iii)
If Principal Accounting Officer’s termination without Cause or resignation for Good Reason occurs as a result of or immediately
prior to the closing of a Change-in-Control (and provided such termination or resignation constitutes a Separation from Service), and
provided that Principal Accounting Officer remains in compliance with the terms of this Agreement and the Company’s policies applicable
to Principal Accounting Officer and satisfies the requirements set forth in Section 4, then in lieu of the benefits set forth in Section
3.2(ii)(a) and (b), Principal Accounting Officer shall receive the following severance benefits:

 

(a)
Severance in an amount equal to the sum of the following (shall be subject to standard payroll deductions and withholdings, and payable
in a lump-sum on the 60th day following Principal Accounting Officer’s Separation from Service):

 

(1)
Fifty-two weeks of Base Salary as in effect immediately prior to the separation date; and

 

(2)
Target bonus equal to the product of (A) Principal Accounting Officer’s Base Salary as in effect immediately prior to the separation
date, multiplied by (B) Principal Accounting Officer’s annual bonus percentage target as in effect immediately prior to the separation
date.

 

(b)
The vesting of all of Principal Accounting Officer’s equity interests in the Company shall be accelerated such that all equity
interests shall be deemed vested and exercisable as of Principal Accounting Officer’s last day of employment.

 

    	3

    	 

    

 

3.3.
Termination for Cause; Resignation Without Good Reason; Death or Disability.

 

(i)
The Company may terminate Principal Accounting Officer’s employment with the Company at any time for Cause. Further, Principal
Accounting Officer may resign at any time without Good Reason. Principal Accounting Officer’s employment with the Company may also
be terminated due to Principal Accounting Officer’s death or disability.

 

(ii)
If Principal Accounting Officer resigns without Good Reason, or the Company terminates Principal Accounting Officer’s employment
for Cause, or upon Principal Accounting Officer’s death or disability, then (a) Principal Accounting Officer will no longer vest
in any equity interests that are subject to vesting, (b) all payments of compensation by the Company to Principal Accounting Officer
under this Agreement will terminate immediately (except as to amounts already earned), and (c) Principal Accounting Officer will not
be entitled to any severance benefits hereunder, including the Severance.

 

4.
Conditions to Receipt of the Severance Benefits. Principal Accounting Officer’s receipt of the severance benefits set forth
in Sections 3.2(ii) and (iii) will be subject to Principal Accounting Officer signing and not revoking a separation agreement and release
of claims in a form reasonably satisfactory to the Company (the “Separation Agreement”). No severance benefits will
be paid or provided until the Separation Agreement becomes effective.

 

5.
Section 409A. It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the greatest
extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A 1(b)(4), 1.409A
1(b)(5) and 1.409A 1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions,
and to the extent no so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section
409A. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A 2(b)(2)(iii)),
Principal Accounting Officer’s right to receive any installment payments under this Agreement (whether severance payments, reimbursements
or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder
shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if
Principal Accounting Officer is deemed by the Company at the time of Principal Accounting Officer’s Separation from Service to
be a “specified employee” for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from
Service set forth herein and/or under any other agreement with the Company are deemed to be “deferred compensation”, then
to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code
Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to Principal Accounting
Officer prior to the earliest of (i) the expiration of the six-month period measured from the date of Principal Accounting Officer’s
Separation from Service with the Company, (ii) the date of Principal Accounting Officer’s death or (iii) such earlier date as permitted
under Section 409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable
Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Paragraph shall be paid in a lump sum to Principal Accounting
Officer, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall
be due on any amounts so deferred.

 

    	4

    	 

    

 

6.
Definitions.

 

(i)
Cause. For purposes of this Agreement, “Cause” for termination means (a) conviction of, or the entry of a plea
of guilty or no contest to, a felony or any crime that may materially adversely affect the business, standing or reputation of the Company;
(b) dishonesty, fraud, embezzlement or other misappropriation of funds; (c) material breach of this Agreement that remains uncured 30
days after written notice of breach; (d) willful refusal to perform the lawful, good faith and reasonable directives of the Company’s
Chief Executive Officer; or (e) termination of Principal Accounting Officer’s employment pursuant to Sections 10.2 and 10.3 of
this Agreement.

 

(ii)
Good Reason. For purposes of this Agreement, Principal Accounting Officer shall have “Good Reason” for resignation
of employment with the Company if any of the following actions are taken by the Company without Principal Accounting Officer’s
prior written consent: (a) a material reduction in Principal Accounting Officer’s Base Salary, unless the reduction is proportional
to an across-the-board decrease affecting all senior Officers; or (b) a material reduction in Principal Accounting Officer’s duties
and responsibilities. Notwithstanding the foregoing, the Company may change Principal Accounting Officer’s duties and responsibilities
to fit the needs of the Company so long as such change(s) do not materially reduce Principal Accounting Officer’s duties to the
Company. In order to resign for Good Reason, Principal Accounting Officer must provide written notice to the Company’s Board within
30 days after the first occurrence of the event giving rise to Good Reason setting forth the basis for Principal Accounting Officer’s
resignation, allow the Company at least 30 days from receipt of such written notice to cure such event, and if such event is not reasonably
cured within such period, Principal Accounting Officer must resign from all positions Principal Accounting Officer then holds with the
Company not later than 90 days after the expiration of the cure period.

 

(iii)
Change-in-Control. For purposes of this Agreement, “Change-in-Control” will have the meaning set forth in the
Amended and Restated Lipocine Inc. 2014 Equity Incentive Plan.

 

7.
Proprietary Information Obligations. Principal Accounting Officer shall be required to execute and abide by the Company’s standard
form of Employee Proprietary Information and Inventions Agreement. Pursuant to Section 8, Principal Accounting Officer shall also be
required to execute and abide by the Company’s form of Employee Restrictive Covenant Agreement.

 

8.
Outside Activities During Employment.

 

8.1.
Non-Company Business. Except with the prior written consent of the Board, Principal Accounting Officer will not during the term of
Principal Accounting Officer’s employment with the Company undertake or engage in any other employment, occupation or business
enterprise, other than ones in which Principal Accounting Officer is a passive investor. Principal Accounting Officer is permitted to
serve as a member of the board of directors of one company provided that such company is not a competitor of the Company. Principal Accounting
Officer may engage in civic and not-for-profit activities so long as such activities do not materially interfere with the performance
of Principal Accounting Officer’s duties hereunder.

 

    	5

    	 

    

 

8.2.
No Adverse Interests. Principal Accounting Officer agrees not to acquire, assume or participate in, directly or indirectly, any position,
investment or interest known to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise.

 

9.
Code Section 280G. If any payment or benefit Principal Accounting Officer would receive from the Company or otherwise in connection
with a Corporate Transaction or other similar transaction (“Payment”) would (i) constitute a “parachute payment”
within the meaning of Section 280G of the Code and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of
the Code (the “Excise Tax”), then such Payment will be equal to the Reduced Amount. The “Reduced Amount”
will be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax,
or (y) the largest portion, up to and including the total, of the Payment, whichever amount ((x) or (y)), after taking into account all
applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal
rate), results in Principal Accounting Officer’s receipt of the greater economic benefit notwithstanding that all or some portion
of the Payment may be subject to the Excise Tax. If a Reduced Amount will give rise to the greater after-tax benefit, the reduction in
the Payments will occur in the following order: (a) reduction of cash payments; (b) cancellation of accelerated vesting of equity awards
in such a manner as to produce the least amount of reduction necessary; and (c) reduction of other benefits paid to Principal Accounting
Officer. Within any such category of payments and benefits (that is, (a), (b) or (c)), a reduction will occur first with respect to amounts
that are not “deferred compensation” within the meaning of Section 409A and then with respect to amounts that are. In the
event that acceleration of compensation from Principal Accounting Officer’s equity awards is to be reduced, such acceleration of
vesting will be canceled, subject to the immediately preceding sentence, in the reverse order of the date of grant, except to the extent
a different chronology is necessary to produce the least amount of reduction. The registered public accounting firm engaged by the Company
for general audit purposes as of the day prior to the effective date of the event described in Section 280G(b)(2)(A)(i) of the Code will
perform the foregoing calculations. If the registered public accounting firm so engaged by the Company is serving as accountant or auditor
for the acquirer or is otherwise unable or unwilling to perform the calculations, the Company will appoint a nationally recognized firm
that has expertise in these calculations to make the determinations required hereunder. The Company will bear all expenses with respect
to the determinations by such independent registered public accounting firm required to be made hereunder. Any good faith determinations
of the independent registered public accounting firm made hereunder will be final, binding and conclusive upon the Company and Principal
Accounting Officer.

 

10.
Further Agreements of Principal Accounting Officer.

 

10.1.
No Restrictions. Principal Accounting Officer warrants and represents that she is not bound by any employment contract, restrictive
covenant or any other restriction preventing Principal Accounting Officer from entering into employment with the Company or limiting
Principal Accounting Officer’s ability to conduct the activities contemplated by this Agreement or to carry out her responsibilities
to the Company, or which is in any other way inconsistent with the terms of this Agreement.

 

    	6

    	 

    

 

10.2.
Documentation. For purposes of federal immigration law, Principal Accounting Officer will be required to provide to the Company documentary
evidence of Principal Accounting Officer’s identity and eligibility for employment in the United States. Principal Accounting Officer
agrees to provide such documentation within three (3) business days of her date of hire. If Principal Accounting Officer does not provide
such documentation within three (3) business days of her date of hire, Principal Accounting Officer’s employment with the Company
may be terminated.

 

10.3.
Background Check. Principal Accounting Officer’s employment under this Agreement is subject to Principal Accounting Officer
passing a standard criminal background check, testing for any recent use of illegal drugs, Food and Drug Administration debarment certification
and any other employment related issues that may negatively affect Principal Accounting Officer’s performance under this Agreement.
Principal Accounting Officer hereby consents to such background check. If Principal Accounting Officer does not pass the criminal background
check, Principal Accounting Officer’s employment with the Company may be terminated.

 

10.4.
Resignation by Principal Accounting Officer. Principal Accounting Officer shall not voluntarily retire, resign or otherwise terminate
her relationship with the Company or any of its affiliates without first giving the Company at least sixty (60) days prior written notice
of the effective date of such retirement, resignation or other termination. Such written notice shall be sent by certified mail to Lipocine
Inc., Attn: President and CEO, 675 Arapeen Dr. Suite 202, SLC, UT 84124. The Company retains the right to waive the notice requirement
in whole or in part or to place you on paid leave for all or part of this sixty (60) day period.

 

10.5.
No Solicitation. Principal Accounting Officer agrees that if her employment is terminated for any reason by either Party, Principal
Accounting Officer shall not for a period of one (1) year after such termination, without the Company’s prior written consent,
directly or indirectly: (a) solicit or induce, or cause or encourage others to solicit or induce, approach, counsel, attempt or cause
or induce, or encourage others to solicit or induce, any employees of the Company to leave the Company; (b) hire or cause others to hire
any employees of the Company; or (c) encourage or assist in the hiring process of any employees of the Company, or cause others to participate,
encourage or assist in the hiring process of any employees of the Company.

 

10.6.
Non-Disclosure of Confidential Information. Principal Accounting Officer shall not at any time, whether during Principal Accounting
Officer’s employment or following the termination of Principal Accounting Officer’s employment, for any reason, directly
or indirectly disclose or furnish to any entity, firm, corporation or person any confidential or proprietary information of the Company
with respect to any aspect of its operation, business or clients. Principal Accounting Officer shall be allowed to disclose confidential
information to the extent that such disclosure is (a) duly approved in writing by the Company; (b) necessary for Principal Accounting
Officer to enforce her rights under this Agreement in connection with a legal proceeding; or (c) required by law or by the order of a
court or similar judicial or administrative body, provided that Principal Accounting Officer notify the Company of such required disclosure
promptly and cooperate with the Company in any lawful action to contest or limit the scope of such required disclosure. Confidential
or proprietary information shall mean information not generally known to the public to which Principal Accounting Officer gains access
by reason of Principal Accounting Officer’s employment by the Company and includes, but is not limited to, information relating
to all present or past customers, trade secrets, business and marketing plans, research and development plans, financial data and strategies,
salaries and employment benefits, and operational costs. This provision shall survive the expiration of this Agreement.

 

    	7

    	 

    

 

10.7.
Company Property. All records, files, memoranda, reports, customer information, client lists, documents and equipment relating to
the business of the Company, whether in electronic or any other format, which Principal Accounting Officer prepares, possesses or comes
in contact with while she is an employee of the Company, shall remain the sole property of the Company. Principal Accounting Officer
agrees upon termination of Principal Accounting Officer’s employment, that Principal Accounting Officer shall provide to the Company
all documents, papers, files, electronic media, or other material in Principal Accounting Officer’s possession and under Principal
Accounting Officer’s control that are connected with or derived from Principal Accounting Officer’s services to the Company.
Principal Accounting Officer agrees that the Company owns all work products, patents, copyrights, trademarks, trade secrets and other
material produced by Principal Accounting Officer during Principal Accounting Officer’s employment with the Company. This provision
shall survive the expiration of this Agreement.

 

10.8.
Remedies. In the event Principal Accounting Officer breaches her obligations under this Agreement, the Company, in addition to being
entitled to exercise all rights granted by the law, including recovery of damages, will be entitled to specific performance of its rights
under this Agreement. Principal Accounting Officer acknowledges that the Company shall suffer irreparable harm in the event of a breach
or prospective breach of any of the provisions of this Section 10 and that any monetary damages would not be adequate relief. Accordingly,
the Company shall be entitled to injunctive relief in any federal or state court of competent jurisdiction located in Salt Lake County
in the State of Utah, or in any state in which Principal Accounting Officer resides.

 

11.
General Provisions.

 

11.1.
Notices. Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery (including personal
delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Principal Accounting
Officer at the address as listed on the Company payroll.

 

11.2.
Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any
applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any
other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping
with the intent of the parties.

 

    	8

    	 

    

 

11.3.
Waiver. Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby
be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.

 

11.4.
Complete Agreement. This Agreement and the other agreements referred to herein constitute the entire agreement between Principal
Accounting Officer and the Company with regard to this subject matter and is the complete, final, and exclusive embodiment of the Parties’
agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation, written
or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. It is
entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified
or amended except in a writing signed by a duly authorized officer of the Company.

 

11.5.
Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than
one party, but all of which taken together will constitute one and the same Agreement.

 

11.6.
Headings. The headings of the paragraphs hereof are inserted for convenience only and shall not be deemed to constitute a part hereof
nor to affect the meaning thereof.

 

11.7.
Successors and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Principal Accounting
Officer and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Principal Accounting
Officer may not assign any of her duties hereunder. In addition, Principal Accounting Officer may not assign any of her rights hereunder
without the written consent of the Company.

 

11.8.
Tax Withholding and Indemnification. All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings
of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Principal Accounting
Officer acknowledges and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any
payments or awards contemplated by or made pursuant to this Agreement. Principal Accounting Officer has had the opportunity to retain
a tax and financial advisor and fully understands the tax and economic consequences of all payments and awards made pursuant to the Agreement.

 

11.9.
Choice of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws
of the State of Utah, without regards to conflicts of law. Any dispute arising out of this Agreement, or the breach thereof, shall be
brought in a court of competent jurisdiction in Salt Lake County, the State of Utah; the parties expressly consenting to venue in Salt
Lake County, the State of Utah. Each Party shall be responsible for its own costs and expenses (including attorney fees) incurred in
connection with the enforcement of such Party’s rights hereunder.

 

[Signature
Page Follows]

 

    	9

    	 

    

 

In
Witness Whereof, the Parties have executed this
Agreement on the date indicated.

 

	 	Lipocine Inc.
	 	 	 
	Date:
    March 7, 2022	By:
    	/s/
    Mahesh Patel
	 	 	Mahesh
    Patel, Ph.D.
	 	 	President
    and CEO
	 	 	 
		PRINCIPAL ACCOUNTING OFFICER
	 	 	 
	Date:
    March 7, 2022	 	/s/
    Krista Fogarty
	 	 	Krista
    Fogarty

 

[Signature Page to Employment Agreement – Krista Fogarty]Alopexx, Inc. S-1 

 

Exhibit 10.4

 

 

[***]
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information
is not material and would likely cause competitive harm if publicly disclosed

 

THE
BRIGHAM AND WOMEN’S HOSPITAL, INC. 

EXCLUSIVE LICENSE AGREEMENT

 

BWH
Agreement No: [***] 

BWH Case No: [***],[***],[***]

 

This
License Agreement (“AGREEMENT”) is made as of the 4th day of December, 2007 (“EFFECTIVE DATE”), between
Alopexx Pharmaceuticals, LLC, a Delaware limited liability company, having a principal place of business at [***](“COMPANY”)
and The Brigham and Women’s Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business
at 75 Francis Street, Boston, MA 02115 (“HOSPITAL”), each referred to herein individually as a “PARTY”
and collectively as the “PARTIES”.

 

RECITALS

 

HOSPITAL,
as a center for patient care, research, and education, is the owner or joint owner of certain PATENT RIGHTS (defined below) and
desires to grant a license of those PATENT RIGHTS to COMPANY in order to benefit the public by disseminating the results of its
research via the commercial development, manufacture, distribution and use of products and processes.

 

HOSPITAL’s
rights to the PATENTS RIGHTS pertaining to BWH Case [***] and its right to grant licenses to those PATENT RIGHTS are governed by
an interinstitutional agreement between HOSPITAL and [***] effective as of November 12, 2004 and as amended on November 30, 2007,
and hereby attached in Appendix [***].

 

COMPANY
has the capability to commercially develop, manufacture, distribute and use PRODUCTS and PROCESSES (defined below) for public
use and benefit and desires to license such PATENT RIGHTS.

 

For
good and valuable consideration, the sufficiency of which is hereby acknowledged, the PARTIES hereto agree as follows:

 

I.
CERTAIN DEFINITIONS

 

The
following terms shall have the following meanings as used herein, unless the context requires otherwise.

 

1.1         “AFFILIATE”
with respect to either PARTY shall mean any corporation or other legal entity other than that PARTY in whatever country
organized, controlling, controlled by or under common control with that PARTY. The term “control” shall mean (a)
in the case of COMPANY, direct or indirect ownership of at least fifty percent (50%) of the voting securities having the
right to elect directors, and (b) in the case of HOSPITAL, the power, direct or indirect, to elect or appoint more than
fifty percent (50%) of the directors or trustees, or to cause direction of management and policies, whether through the
ownership of voting securities, by contract or otherwise.

 

     

     

    

 

1.2        
“BIOLOGICAL MATERIALS” shall mean the biological materials and assays set forth in Appendix B.

 

1.3         “CLAIM”
shall mean any pending or issued claim of any PATENT RIGHT that has not been permanently revoked, nor held unenforceable or
invalid by a decision of a court or other governmental agency of competent jurisdiction that is unappealable or unappealed in
the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer
or otherwise.

 

1.4        
“COMMERCIAL SALE” shall mean any TRANSFER of a PRODUCT or PROCESS by COMPANY, an AFFILIATE or SUBLICENSEE (which
may include a TRANSFER to an AFFILIATE or SUB LICENSEE), for value, in the form of cash or otherwise.

  

1.5         
“[***]”shall mean [***].

 

1.6         
“[***] LICENSE” shall mean the license agreement between [***] and HOSPITAL effective
as of [***] (BWH Agreement No. [***]) and any amendments to that agreement.

 

1.7          “KLP”
shall mean KLP Enterprises LLC.

  

1.8          “LICENSE
FIELD” shall mean [***] including all:

 

(i)
[***].

(ii)
[***] .

 

Specifically
excluded from LICENSE FIELD are [***]

 

	1.8	“LICENSE
                                         TERRITORY” shall mean worldwide.

  

    2 

     

    

 

	1.9	“NET
                                         SALES”
                                         shall
                                         mean:

 

		(a)	the
                                         greatest of the gross amount billed, invoiced or received by COMPANY, its AFFILIATES
                                         and SUBLICENSEES (for the purposes of this Section 1.9, each a “SELLER”)
                                         for TRANSFER of PRODUCTS and PROCESSES by a SELLER to third parties (but excluding (i)
                                         any amounts billed, invoiced or received resulting from any TRANSFER
                                         of
                                         any PRODUCT or PROCESS between or among COMPANY, an AFFILIATE or any SUBLICENSEE, unless
                                         the transferee is the final purchaser of such PRODUCT or PROCESS; and (ii) any royalty
                                         or similar payment by SUBLICENSEE to AFFILIATE or COMPANY, or by AFFILIATE to COMPANY,
                                         on account of a TRANSFER of any PRODUCT or PROCESS by a SUBLICENSEE or AFFILIATE, as
                                         the case may be, to a third party), less (to the extent appropriately documented)
                                         the following amounts actually paid or otherwise incurred by SELLER in effecting such
                                         TRANSFER:

 

		(i)	credits
                                         and allowances by reason of rejection or return;

 

		(ii)	reasonable
                                         and customary rebates, discounts and chargebacks;

 

		(iii)	amounts
                                         for outbound transportation, insurance,
                                         handling
                                         and shipping, to the extent separately invoiced;

 

		(iv)	taxes,
                                         customs duties and other governmental charges levied on or measured by COMMERCIAL SALES,
                                         to the extent separately itemized or invoiced, whether paid by or on behalf of COMPANY
                                         so long as COMPANY’s price is reduced thereby, but not franchise or income taxes
                                         of any kind whatsoever.

 

		(b)	NET
                                         SALES shall occur on the earlier
                                         of
                                         the date of billing or invoicing for TRANSFER of a PRODUCT or PROCESS. For a PRODUCT
                                         or PROCESS for which SELLER does not bill or invoice, NET SALES shall occur on the date
                                         on which payment is due or made to the SELLER, whichever is earlier. If the date on which
                                         such payment is due or made cannot be ascertained.
                                         NET
                                         SALES shall
                                         be
                                         deemed to have occurred on the date the PRODUCT or PROCESS was TRANSFERRED.

 

		(c)	Subject
                                         to Section 1.9(a)(ii), if a SELLER TRANSFERS any PRODUCT or PROCESS at a discounted price
                                         that is not part of a reasonable and customary marketing and sales program, or for non-cash
                                         consideration, NET SALES shall be calculated based on the non-discounted cash amount
                                         charged to an independent third party for the PRODUCT or PROCESS during the same REPORTING
                                         PERIOD or, in the absence of such transaction, on the fair market value
                                         of
                                         the PRODUCT or PROCESS.

  

    3 

     

    

 

		(d)	In
                                         the case of a TRANSFER of a PRODUCT within COMPANY or between or among COMPANY, any AFFILIATE
                                         or SUBLICENSEE, solely for further TRANSFER by such transferee, NET SALES shall be based
                                         on the further TRANSFER of such PRODUCT by such transferee.

 

1.10      
“PATENT RIGHTS” shall mean HOSPITAL’s rights and [***]’s rights in (a) patents and patent applications
listed on Appendix C attached hereto; (b) any divisions, continuations, continuations-in-part to the extent the claims
are supported by the patent applications and patents included in (a), reissues, reexaminations or extensions of the patent applications
and patents in (a); (c) any foreign counterparts and equivalents of the patent applications and patents listed in (a) and (b);
and (d) all patents issuing therefrom anywhere in the world. For clarity, the PATENT RIGHTS are separated into 2 parts. BWH Case
[***] is jointly owned by HOSPITAL and [***]. BWH Cases [***] and [***] are solely owned by HOSPITAL.

 

	1.11	“PROCESS”
                                         shall mean any process, method or service the use or performance of which, in whole
                                         or in part:

 

		(a)
	absent the license granted hereunder would infringe
or is covered by, one or more CLAIMS of PATENT RIGHTS; or

 

		(b)	employs
                                         TECHNOLOGICAL INFORMATION.

 

	1.12	“PRODUCT”
                                         shall mean any article, device or composition, the manufacture, use, or sale of which,
                                         in whole or in part:

 

		(a)	 absent the license granted hereunder would infringe
or is covered by, one or more CLAIMS of PATENT RIGHTS; or

 

		(b)	employs
                                         TECHNOLOGICAL INFORMATION.

 

1.13      
“PURCHASE AGREEMENT” shall mean the Securities Purchase Agreement by and between COMPANY and KLP dated December
4, 2007, hereby attached as Appendix D.

 

1.14      
“REPORTING PERIOD” shall mean each three month period ending March 31, June 30, September 30 and December 31.

 

1.15      
“SUBLICENSEE” shall mean any third party sublicensee of the rights granted by COMPANY
under Section 2.1(a)(ii).

 

1.16        “TECHNOLOGICAL
INFORMATION” shall mean any research data, designs, formulae, process information and other information pertaining to any
invention claimed in the PATENT RIGHTS for which there is no obligation to any third party which is either (a) disclosed by Dr. Pier
under Section 2.5, or (b) contained in a pending application for a PATENT RIGHT. Technological Information shall include the
BIOLOGICAL MATERIALS.

  

    4 

     

    

 

1.17      
“TRANSFER” shall mean to sell or have sold, to lease or have leased, to import or have imported or otherwise
to transfer or have transferred, for value in the form of cash or otherwise, a PRODUCT or PROCESS, and further in the case of
a PROCESS to use or perform such PROCESS for the benefit of a third party.

 

2.
LICENSE

 

	2.1	Grant
                                         of License.

 

		(a)	Subject
                                         to the terms of this AGREEMENT, HOSPITAL hereby grants to COMPANY in the LICENSE FIELD
                                         in the LICENSE TERRITORY:

 

		(i)	an
                                         exclusive, royalty-bearing license under PATENT RIGHTS to make, have made, use, have
                                         used, and TRANSFER PRODUCTS and to use, have used and TRANSFER PROCESSES;

 

		(ii)	the
                                         right to grant sublicenses under the rights granted in Section 2.l(a)(i) to SUBLICENSEES,
                                         provided that in each case COMPANY shall be responsible for the performance of any obligations
                                         of SUBLICENSEES relevant to this AGREEMENT as if such performance were carried out by
                                         COMPANY itself, including, without limitation, the payment of any royalties or other
                                         payments provided for hereunder, regardless of whether the terms of any sublicense provide
                                         for such amounts to be paid by the SUBLICENSEE directly to HOSPITAL; and

 

		(iii)	the
                                         nonexclusive right to disclose, use and transfer TECHNOLOGICAL INFORMATION disclosed
                                         by HOSPITAL to COMPANY hereunder.

 

		(b)	The
                                         licenses granted in Section 2.l(a) above include the right to grant to the purchaser
                                         of PRODUCTS from COMPANY, AFFILIATES and SUBLICENSEES the right to use such purchased
                                         PRODUCTS in a method coming within the scope of PATENT RIGHTS.

 

		(c)	The
                                         foregoing license grant shall include the grant of said license to any AFFILIATE of COMPANY,
                                         provided that such AFFILIATE shall assume the same obligations as those of COMPANY and
                                         be subject to the same terms and conditions hereunder and further provided that COMPANY
                                         shall be responsible for the performance by said AFFILIATE of said obligations and for
                                         compliance by said AFFILIATE with said terms and conditions. COMPANY shall provide to
                                         HOSPITAL a fully signed, non-redacted copy of each agreement with each AFFILIATE
                                         that assumes the aforesaid obligations, including all exhibits, attachments and related
                                         documents and any amendments, within thirty (30) days of request by HOSPITAL.

  

    5 

     

    

 

2.2         Sublicenses.
All sublicenses granted hereunder shall be consistent with the terms of this AGREEMENT, shall incorporate terms and conditions
sufficient to enable COMPANY to comply with this AGREEMENT and shall prohibit any further sublicense by a SUBLICENSEE. Any
sublicense granted by COMPANY shall be subject to the prior written approval of HOSPITAL, which approval shall not be unreasonably
withheld or delayed. COMPANY shall remain joint and severally liable with SUBLICENSEES for performance and payment requirements of
sublicenses. COMPANY shall provide to HOSPITAL a fully signed non-redacted copy of all sublicense agreements and amendments thereto,
including all exhibits, attachments and related documents, within thirty (30) days of executing the same. Upon termination of this
AGREEMENT or any license granted hereunder for any reason, any sublicenses shall be addressed in accordance with Section
10.6.

 

2.3         
Retained Rights; Requirements. Any and all licenses granted hereunder are subject to:

 

		(a)	HOSPITAL’s,
                                         [***]’s and their AFFILIATES’ right to make and to use the subject matter described
                                         and/or claimed in the PATENT RIGHTS and to permit others at academic, government and
                                         not-for-profit institutions to make and use the subject matter described and/or claimed
                                         in PATENT RIGHTS for research and educational purposes; and

 

		(b)	for
                                         PATENT RIGHTS supported by federal funding, the rights, conditions and limitations imposed
                                         by U.S. law (see 35 U.S.C. § 202 et seq and regulations pertaining thereto), including
                                         without limitation:

 

		(i)	the
                                         royalty-free non-exclusive license granted to the U.S. government; and

 

		(ii)	the
                                         requirement that any PRODUCTS used or sold in the United States shall be manufactured
                                         substantially in the United States.

 

2.4          No
Additional Rights. It is understood that nothing in this AGREEMENT shall be construed to grant COMPANY a license express or
implied under any patent owned solely or jointly by HOSPITAL or BIDMC other than the PATENT RIGHTS expressly licensed hereunder.
HOSPITAL and BIDMC shall have the right to license any PATENT RIGHTS to any other party for any purpose outside of the LICENSE FIELD
or the LICENSE TERRITORY.

 

2.5          Disclosure
of TECHNOLOGICAL INFORMATION. At COMPANY’s request prior
to execution of this AGREEMENT, HOSPITAL (through Dr. Gerald Pier) shall use reasonable efforts to disclose within thirty (30) days
after execution of this AGREEMENT any TECHNOLOGICAL INFORMATION beyond that disclosed in the patent application for the PATENT
RIGHTS which is then known to Dr. Pier and which he or she reasonably believes is necessary for COMPANY to utilize the licenses
granted hereunder.

  

    6 

     

    

  

3.
DUE DILIGENCE OBLIGATIONS

 

3.1         
Diligence Requirements. COMPANY shall itself use, or shall cause its AFFILIATES or SUBLICENSEES, as applicable, to use,
best efforts to develop and make available to the public PRODUCTS and PROCESSES throughout the LICENSE TERRITORY in the LICENSE
FIELD. Such efforts shall include achieving the following objectives within the time periods designated below following the EFFECTIVE
DATE:

 

		(a)	Pre-Sales
                                         Requirements.

 

		(i)	Within
                                         [***] of the EFFECTIVE DATE and annually thereafter as set forth in Section 5.1, COMPANY
                                         shall submit a research and development plan to HOSPITAL;

		(ii)	Within
                                         [***], COMPANY will [***];

		(iii)	Within
                                         [***] COMPANY will [***];

		(iv)	Within
                                         [***] COMPANY  [***];

		(v)	Within
                                         [***] COMPANY  [***]; and

		(vi)	Within
                                         [***] COMPANY  [***].

 

		(b)	Post-Sales
                                         Requirements.

 

		(i)	Following
                                         the first COMMERCIAL SALE in any country in the LICENSE TERRITORY, COMPANY shall itself
                                         or through its AFFILIATES and/or SUBLICENSEES make continuing COMMERCIAL SALES in such
                                         country without any elapsed time period of one (1) year or more in which such COMMERCIAL SALES
                                         do not occur.

 

Achievement
of the foregoing objectives shall be deemed to satisfy COMPANY’s obligations to use best efforts under this Section 3 .1.

 

		3.2         
                              Adjustment to Diligence Requirement Deadlines by Payment. If requested by COMPANY and at
                              the sole discretion of HOSPITAL, COMPANY may extend for [***] the achievement of a diligence requirement
                              described in the above 3.1(a)(i-vi) or 3.1(b)(i) by giving written notice to the HOSPITAL prior
                              to the deadline for the requirement and by making a non-refundable, non-creditable extension payment
                              of [***] to HOSPITAL within thirty (30) days of sending such notice. Such extensions shall be granted to COMPANY
                              no more one (1) than time per specific diligence requirement and no more than three (3) times overall.

  

    7 

     

    

 

 

3.3        
Diligence Failures. If HOSPITAL determines that COMPANY has failed to fulfill any of its obligations under Section 3.1,
then HOSPITAL may treat such failure as a default and may terminate this AGREEMENT and/or the licenses granted hereunder in accordance
with Section 10.4.

 

3.4        
Diligence Reports. COMPANY shall provide all reports with respect to its obligations under Section 3.1 as set forth in
Article 5.

 

4.
PAYMENTS AND ROYALTIES

 

4.1        
License Issue Fee. COMPANY shall pay HOSPITAL a non-refundable license issue fee in the sum of [***] to be made payable according
to the following schedule:

 

(i)  payment in the amount of [***] shall be due upon execution of this AGREEMENT;

 

(ii)
payment in the amount of [***] shall be due on [***]; and

 

(iii)
payment in the amount of [***] shall be due on [***].

 

4.2         Patent
Cost Reimbursement for BWH Case [***]. COMPANY shall reimburse HOSPITAL for all costs associated with the
preparation, filing, prosecution and maintenance of certain PATENT RIGHTS for BWH Case [***] which are directed toward the
antibody (“CASE [***] PATENT COSTS”). As of the EFFECTIVE DATE, HOSPITAL has incurred approximately [***] in CASE [***]
PATENT COSTS which amount COMPANY shall pay to HOSPITAL in [***] installments which shall be made payable according to the
following schedule:

 

		(i)	payment
                                         in the amount of [***] shall be due upon execution of this AGREEMENT;

 

		(ii)	payment
                                         in the amount [***] shall be due on [***];

  

    8 

     

    

 

		(iii)	payment
                                         in the amount of [***] shall be due on [***];

 

		(iv)	payment
                                         in the amount of [***] shall be due on [***];

 

		(v)	payment
                                         in the amount of [***] shall be due on [***].

 

COMPANY
shall pay to HOSPITAL, or at HOSPITAL’s request directly to patent counsel, all other CASE [***] PATENT COSTS within thirty
(30) days of COMPANY’s receipt of an invoice for such CASE [***] PATENT COSTS either from HOSPITAL or HOSPITAL’s patent
counsel. COMPANY agrees to indemnify, defend and hold HOSPITAL and [***] harmless from and against any and all liabilities, damages,
costs and expenses arising from the failure of COMPANY to timely pay such invoices and CASE [***] PATENT COSTS. HOSPITAL shall
instruct patent counsel to provide copies to HOSPITAL for HOSPITAL’s administrative files of all invoices detailing CASE [***]
PATENT COSTS which are sent directly to COMPANY. 

 

	4.3	Patent
                                         Cost Reimbursement for BWH Cases [***] and [***].

 

		(a)	In
                                         addition to the CASE [***] PATENT COSTS, there are certain patent costs associated with
                                         the PATENT RIGHTS for BWH Cases [***] and [***] (which are directed toward the antigen and
                                         are solely owned by HOSPITAL) which have been and are currently being paid by [***] under
                                         the terms of the [***]. Under the terms of the [***], in the event HOSPITAL licenses a portion
                                         of the PATENT RIGHTS to a third party, HOSPITAL and [***], in good faith, must negotiate
                                         a reduction in past and future amounts of [***] PATENT
COSTS paid and payable by [***]. Such a reduction in [***] PA TENT COSTS may require payments by HOSPITAL to [***].

 

		(b)	Company
                                            acknowledges and agrees that it will be responsible for paying a share of future [***] PATENT
                                            COSTS and will reimburse HOSPITAL for any payments by HOSPITAL to [***] for past [***] PATENT
                                            COSTS (each as negotiated by HOSPITAL and [***]) so long as such payments are fair and reasonable
                                            in light of the relative rights held by [***] and the COMP ANY in the PATENT RIGHTS. At such
                                            time that COMPANY begins to pay a portion of future [***] PATENT COSTS, COMPANY shall pay
                                            to HOSPITAL, or at HOSPITAL's request directly to patent counsel, [***] PATENT COSTS within
                                            thirty (30) days of COMPANY's receipt of an invoice for such [***]. PATENT COSTS either from
                                            HOSPITAL or HOSPITAL's patent counsel. COMPANY agrees to indemnify, defend and hold HOSPITAL
                                            harmless from and against any and all liabilities, damages, costs and expenses arising from
                                            the failure of COMPANY to timely pay such invoices and [***] PATENT COSTS.
HOSPITAL shall instruct patent counsel to provide copies to HOSPITAL for HOSPITAL's administrative files of all invoices detailing [***]
PATENT COSTS which are sent directly to COMPANY.

  

    9 

     

    

  

		(c)	HOSPITAL
                                            shall keep COMPANY apprised of its negotiations with GSK and when the negotiations are completed,
                                            HOSPITAL and COMPANY shall enter into a separate written agreement or shall amend this AGREEMENT
                                            to reflect the amount of [***] PATENT COSTS owed by COMP ANY to HOSPITAL and/or [***]. If,
                                            after negotiations are completed and an amount is determined, COMPANY fails to pay its share
                                            of GSK PATENT COSTS, COMPANY shall have no further rights in BWH CASES [***] and [***]. Once
                                            an amount is determined, COMPANY shall indemnify, defend and hold harmless HOSPITAL against
                                            any liability damage, loss or expense (including reasonable attorney's fees and expenses
                                            of litigation) incurred by or imposed upon HOSP ITAL as a result of a claim, suit or action
                                            by [***] against HOSPITAL due to COMPANY's failure to pay its share of [***]  PATENT COSTS.

 

4.4       
Deferred License Issue Fee. COMPANY shall pay HOSPITAL a non-refundable license issue fee in the sum of [***] to be made
payable on the [***] of the EFFECTIVE DATE of this AGREEMENT;

 

4.5        Annual
License Fee. COMPANY shall pay to HOSPITAL the following amounts as an annual license fee within sixty (60) days after the end
of the REPORTING PERIOD in which each of the following anniversaries of the EFFECTIVE DATE occurs:

 

		(a)	the
                                         [***] of the EFFECTIVE DATE: [***]

 

		(b)	the
                                         [***] of the EFFECTIVE DATE: [***]

 

		(c)	the
                                         [***] of the EFFECTIVE DATE: [***] and

 

		(d)	the
                                         [***] of the EFFECTIVE DATE: [***]; and

 

		(e)	the
                                         [***] anniversary and on [***] of the EFFECTIVE DATE thereafter: [***].

 

The
annual license fee is nonrefundable; provided however, it shall be credited against royalties subsequently due on NET SALES made
during the twelve-month period following the date of the applicable anniversary payment, if any, but shall not be credited against
royalties due on NET SALES made in any other period.

 

    10 

     

    

	4.6	Milestone
                                            Payments. In addition to the payments set forth in Sections 4.1 through 4.5       above,
                                            COMPANY shall pay HOSPITAL milestone payments of One Million One Hundred and Twenty-Five
                                            Thousand Dollars ($1,125,000) for each PRODUCT or PROCESS, as follows:

		(a)	[***]
                                            within [***] of initiation of Phase II clinical trials; and

		(b)	[***]
                                            within [***] of initiation of Phase III clinical trials; and

		(c)	[***]
                                            within [***] of filing of an NDA or BLA.

(d)     [***]
within [***] of the first COMMERCIAL SALE ([***] of this milestone payment shall be credited against royalties subsequently due on NET
SALES made during the twelve-month period following the date of the first COMMERCIAL SALE, if any, but shall not be credited against
royalties due on NET SALES made in any other period).

 

 

 

4.7       Royalties.

	 	(a)	Beginning
                                            with the first COMMERCIAL SALE in any country in the LICENSE TERRITORY, COMPANY shall pay
                                            HOSPITAL:

		(i)	during
                                            the term of any license granted under Section 2.1 (a)(i)-(ii), a royalty of [***] of the
                                            NET SALES of all PRODUCTS and PROCESSES as described in Sections I.I !(a), and l.12(a), respectively;
                                            and

		(ii)	during
the term of any license granted under Section 2.1(a)(iii), a royalty of [***] of the NET SALES ofall PRODUCTS and PROCESSES as described
in Sections I.I l(b) and l.12(b), respectively, for which no royalty is payable under Section 4.7(a)(i) (however, if COMPANY can demonstrate
that at the time of the sale there is at least one competitive product on the market which holds at least [***] of the market share,
then such royalty shall be reduced and the percentage reduction shall be negotiated in good faith by the parties at the time for education.
There shall be no other offsets or reductions in any royalty payments due under Section 4.7).

 

 

 

    11 

     

    

 

		(b)	If
                                         more than one royalty rate is applicable to a PRODUCT or PROCESS, only the highest of
                                         the applicable royalty rates shall apply.

 

		(c)	In
                                         the event that TRANSFER of a PRODUCT or PROCESS occurs through a distributor which is
                                         not an AFFILIATE or SUBLICENSEE, HOSPITAL shall be entitled to receive an increase in
                                         the royalty payable under this Section 4.7 equivalent to what HOSPITAL would have received
                                         if COMPANY had distributed such PRODUCT or PROCESS itself or through an AFFILIATE or
                                         SUBLICENSEE.

 

		(d)	All
                                         payments due to HOSPITAL under this Section 4. 7 shall be due and payable by COMPANY
                                         within thirty (30) days after the end of each REPORTING PERIOD and shall be accompanied by a report
                                         as set forth in Article 5.4.

 

4.8           Non-Royalty
Income. COMPANY shall pay HOSPITAL within thirty (30) days of receipt thereof a percentage of any and all non-royalty income
attributable to the PRODUCT or PROCESS, including without limitation any payment due to COMPANY or an AFFILIATE in consideration for
the sublicensing of any license granted hereunder or distribution of any PRODUCT or PROCESS, including but not limited to
up-front license fees, license issue fees, maintenance fees, payments pertaining to distribution rights, milestone payments or the
fair market value of any non-cash consideration but excluding any amount included in NET SALES. Non-royalty income payments
shall be made according to the following:

 

	Until
    the following Milestone	Percentage
                                         of Non-Royalty 

                                         Income 

        

	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

 

4.9          Assignment
Fee. COMPANY shall have the right to transfer the license granted in Section 2.1 to a successor of the business interest
of COMPANY provided COMPANY pays a one-time assignment fee of [***] within [***] of such assignment. [***] of the assignment fee shall be
payable to HOSPITAL if KLP exercises its rights as a secured creditor following a default by COMPANY under the PURCHASE AGREEMENT
or under any related instrument, document or agreement. The full assignment fee shall be paid by any TRANSFEREE (as defined
in Section 12.6) within thirty (30) days of such transfer.

  

    12 

     

    

 

4.10      
Form of Payment. All payments due under this AGREEMENT shall be drawn on a United States bank and shall be payable in United
States dollars. Each payment shall reference this AGREEMENT and identify the obligation under this AGREEMENT that the payment
satisfies. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States,
as reported in The Wall Street Journal, on the last working day of the applicable REPORTING PERIOD. Such payments shall be without
deduction of exchange, collection or other charges, and, specifically, without deduction of withholding or similar taxes or other
government imposed fees or taxes, except as permitted in the definition of NET SALES. Checks for all payments due to HOSPITAL
under this AGREEMENT shall be made payable to HOSPITAL and addressed as set forth in Section 12.2. Payments via wire transfer
should be made as follows:

 

Account
[***]

[***]

 

4.11       Overdue
Payments. Any payment due under this AGREEMENT shall, if overdue,
bear interest beginning on the first day following the date such payment was due and shall continue until the payment is made.
Interest shall be at a per annum rate equal to [***] above the prime rate in effect on the due date as reported by The Wall Street
Journal, not to exceed the maximum interest rate permitted by law. Any such overdue payments when made shall be accompanied by all
interest so accrued. Said interest and the payment and acceptance thereof shall not preclude HOSPITAL from exercising any other
rights it may have as a consequence of the lateness of any payment.

 

5.
REPORTS AND RECORDS

 

5.1         Diligence
Reports. Within sixty (60) days after the end of each calendar year, COMPANY shall report in writing to HOSPITAL on progress
made toward the objectives set forth in Section 3.1 during such preceding 12-month period, including, without limitation, progress on
research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses
entered into and marketing.

 

5.2        
Milestone Achievement Notification. COMPANY shall report to HOSPITAL the dates on which it achieves the milestones set
forth in Section 4.6 within sixty (60) days of each such occurrence.

  

    13 

     

    

 

5.3   Non-Royalty
Income Reports. COMPANY shall, along with delivering payment as set forth in Section 4.8, report to HOSPITAL within [***]
of receipt the amount of all non-royalty income received by COMPANY, and COMPANY’S calculation of the amount due and
paid to HOSPITAL from such income, including an itemized listing of the source of income comprising such consideration,
and the name and address of each entity making such payments.

 

5.4         COMMERCIAL
SALES Reports. COMPANY shall report to HOSPITAL the date on which it achieves the first COMMERCIAL SALE in each country of the
LICENSE TERRITORY within [***] of each such occurrence. Following
the first COMMERCIAL SALE, COMP ANY shall deliver reports to HOSPITAL within thirty (30) days after the end of each REPORTING
PERIOD. Each report under this Section 5.4 shall have substantially the format outlined in Appendix E, shall be certified as
correct by an officer of COMPANY and shall contain at least the following information as may be pertinent to a royalty accounting
hereunder for the immediately preceding REPORTING PERIOD:

 

		(a)	the
                                         number of PRODUCTS and PROCESSES TRANSFERRED by COMPANY, its AFFILIATES and SUBLICENSEES
                                         in each country;

 

		(b)	the
                                         gross amount billed, due and paid to COMPANY, its AFFILIATES and SUBLICENSEES for each
                                         PRODUCT and PROCESS, in each country, and total billings or payments due or made for
                                         all PRODUCTS and PROCESSES;

 

		(c)	calculation
                                         of NET SALES for the applicable REPORTING PERIOD in each country, including an itemized
                                         listing of permitted offsets and deductions;

 

		(d)	total
                                         royalties payable on NET SALES in U.S. dollars, together with the exchange rates used
                                         for conversion; and

 

		(e)	any
                                         other payments due to HOSPITAL under this AGREEMENT.

 

If
no amounts are due to HOSPITAL for any REPORTING PERIOD, the report shall so state.

 

5.5          Audit
Rights. COMPANY shall maintain and shall cause each of its AFFILIATES and SUBLICENSEES
to maintain, complete and accurate records relating to the rights and obligations under this AGREEMENT and any amounts payable to
HOSPITAL in relation to this AGREEMENT, which records shall contain sufficient information to permit HOSPITAL
and its representatives to confirm the accuracy of any payments and reports delivered
to HOSPITAL and compliance in all other respects with this AGREEMENT. COMPANY shall retain
and make available, and shall cause each of its AFFILIATES and SUBLICENSEES to retain and
make available, such records for at least five (5) years following the end of
the calendar year to which they pertain, to HOSPITAL and/or its representatives,
at HOSPITAL's expense and upon at least fifteen (15) days' advance written notice, for inspection during normal business hours,
to verify any reports and payments made and/or compliance in other respects under this AGREEMENT. If any examination conducted by
HOSPITAL or its representatives pursuant to the provisions of this Section show an
underreporting or underpayment of five percent
(5%) or more in any payment due to HOSPITAL hereunder,
COMPANY shall bear the full cost of such audit and shall remit any amounts due to HOSPITAL (including interest due in accordance
with Section 4.11) within thirty (30) days of receiving notice thereof from HOSPITAL. If
such examination shows any overpayment of five percent (5%) or more in any payment due
HOSPITAL, HOSPITAL shall remit the overpayment amount to COMPANY within thirty (30) days of the determination of an
overpayment.

  

    14 

     

    

 

6.
PATENT PROSECUTION AND MAINTENANCE

 

6.1          Prosecution. HOSPITAL
shall be responsible for the preparation, filing, prosecution and maintenance of all patent applications and patents included in
PATENT RJGHTS. COMPANY shall reimburse HOSPITAL for CASE [***] PATENT COSTS and its share of [***] PATENT COSTS (hereinafter
collectively referred to as the “PATENT COSTS”) incurred by HOSPITAL relating thereto in accordance with Section 4.2
and 4.3. COMPANY shall have the right to consult with HOSPITAL in the preparation, filing, prosecution and maintenance of
patents and patent applications included in PATENT RJGHTS. 

 

6.2         
Copies of Documents. With respect to any PATENT RIGHT, HOSPITAL shall instruct the patent counsel prosecuting such PATENT
RJGHT to copy COMPANY on patent prosecution documents that are received from or filed with the United States Patent and Trademark
Office.

 

6.3          COMPANY’s
Election Not to Proceed. COMPANY may elect to surrender any patent or patent application in PATENT RJGHTS in any country upon
sixty (60) days advance written notice to HOSPITAL. Such notice shall relieve COMPANY from the obligation to pay for future PATENT
COSTS but shall not relieve COMPANY from responsibility to pay PATENT COSTS incurred prior to the expiration of the sixty (60) day
notice period. Such U.S. or foreign patent application or patent shall thereupon cease to be a PATENT RJGHT hereunder, COMPANY shall
have no further rights therein and HOSPITAL shall be free to license its rights to that particular U.S. or foreign patent
application or patent to any other party on any terms.

 

7.
INFRINGEMENT

 

7.1          HOSPITAL
Right to Prosecute. HOSPITAL will protect the PATENT RIGHTS from infringement and prosecute infringers when, in its sole
judgment, such action may be reasonably necessary, proper and justified. If COMPANY becomes aware of an infringement of a claim of a
PATENT RIGHT by a third party which poses a material threat to COMPANY’S rights under this AGREEMENT, COMPANY may by notice
request HOSPITAL to take steps to protect the PATENT RIGHT. HOSPITAL shall notify COMPANY within two (2) months of the receipt of
such notice whether HOSPITAL intends to prosecute the alleged infringement. If HOSPITAL notifies COMPANY that it intends to so
prosecute, HOSPITAL shall, within two (2) months of its notice to COMPANY either (i) cause such infringement to terminate, or (ii)
initiate legal proceedings against the infringer. 

 

    15 

     

    

 

7.2         COMPANY
Right to Prosecute. In the event HOSPITAL notifies COMPANY that HOSPITAL does not intend to prosecute
infringement identified under Section 7.1, COMPANY may, upon notice to HOSPITAL, initiate legal proceedings against the
infringer at COMPANY’s expense. Before commencing such action, COMPANY and, as applicable, any AFFILIATE, shall consult
with HOSPITAL and shall give careful consideration to the views of HOSPITAL regarding the advisability of the proposed action
and its potential effects on the public interest. COMPANY shall indemnify and hold HOSPITAL and [***] harmless from all costs,
expenses and liabilities that HOSPITAL or [***] incurs in connection with such action, regardless of whether HOSPITAL or [***] is
a party-plaintiff, except for the expense of any independent counsel retained by HOSPITAL in accordance with Section 7.5
below.

 

7.3         Assignment
of PATENT RIGHT. If COMPANY elects to commence an action as described in Section 7.2 above, HOSPITAL shall have, in its
sole discretion, the option to permit such action to be brought in its name and to be joined as a party-plaintiff if
so required by law, or to assign to COMPANY all of HOSPITAL’s right, title and interest in and to the PATENT RIGHT
which is the subject of such action (subject to all of HOSPITAL’s obligations to the government under law and any other
rights that others may have in such PATENT RIGHT). If HOSPITAL makes such an assignment, such assignment shall be
irrevocable, and such action by COMPANY shall thereafter be brought or continued without HOSPITAL as a party, if HOSPITAL is
no longer an indispensable party; provided, however, that COMP ANY shall continue to meet all of its obligations under this
AGREEMENT as if the assigned PATENT RIGHT were still licensed to COMPANY.

 

7.4         
Settlement. COMPANY shall not enter into any settlement, consent judgment or other voluntary final disposition of any infringement
action without the prior written consent of HOSPITAL.

 

7.5          Cooperation.
Each PARTY agrees to cooperate reasonably in any action under this Article 7 which is controlled by the other PARTY, provided
that the controlling PARTY reimburses the cooperating PARTY on a current basis for any costs and expenses incurred by the
cooperating PARTY in connection with providing such assistance, except for the expense of any independent counsel retained by
the cooperating PARTY which shall be reimbursed as set forth below. Such controlling PARTY shall keep the cooperating
PARTY informed of the progress of such proceedings and shall make its counsel available to the cooperating PARTY. The
cooperating PARTY shall be entitled to independent counsel in such proceedings but at its own expense, said expense to be
reimbursed only if any damages are received by the PARTY bringing suit.

  

    16 

     

    

 

7.6        
Recovery. Any award paid by third parties as the result of such proceedings (whether by way of settlement or otherwise)
shall first be applied to reimbursement of the unreimbursed third-party legal fees and expenses incurred by either PARTY and then
the remainder shall be divided between the PARTIES as follows:

 

		(a)	(i)if
                                            the amount is based on lost profits, COMPANY shall receive an amount equal to the damages
                                            the court determines COMPANY has suffered as a result of the infringement less the amount
                                            of any royalties and other payments that would have been due HOSPITAL on TRANSFERS of PRODUCT
                                            and PROCESSES lost
by COMPANY and any other lost opportunities, as a result of the infringement; and

		(i)	HOSPITAL
                                            shall receive an amount equal to the royalties and other payments it would have received
                                            if such TRANSFERS had been made and such other opportunities captured by COMPANY; and

 

		(b)	awards
                                            other than those based on lost profits shall be shared equally by the PARTIES.

 

8. 
INDEMNIFICATION AND INSURANCE

 

	8.1 
                                         	Indemnification.

 

		(a)	COMPANY
                                         shall indemnify, defend and hold harmless HOSPITAL, [***], their AFFILIATES, and their
                                         respective trustees, directors, officers, medical and professional staff, employees,
                                         and agents and their respective successors, heirs and assigns (the “INDEMNITEES”),
                                         against any liability, damage, loss or expense (including reasonable attorney’s
                                         fees and expenses of litigation) incurred by or imposed upon the INDEMNITEES or any one
                                         of them in connection with any claims, suits, actions, demands or judgments arising out
                                         of any theory of product liability (including, but not limited to, actions in the form
                                         of tort, warranty, or strict liability) concerning any product, process or service made,
                                         used or sold pursuant to any right or license granted under this AGREEMENT.

 

		(b)	COMPANY
                                         agrees, at its own expense, to provide attorneys reasonably acceptable to HOSPITAL to
                                         defend against any actions brought or filed against any party indemnified hereunder with
                                         respect to the subject of indemnity contained herein, whether or not such actions are
                                         rightfully brought; provided, however, that any INDEMNITEE shall have the right to retain
                                         its own counsel, at the expense of COMPANY, if representation of such INDEMNITEE by counsel
                                         retained by COMPANY would be inappropriate because of actual or potential differences
                                         in the interests of such INDEMNITEE and any other party represented by such counsel.
                                         COMPANY agrees to keep HOSPITAL informed of the progress in the defense and disposition
                                         of such claim and to consult with HOSPITAL prior to any proposed settlement.

  

    17 

     

    

 

		(c)	This
                                         section 8.1 shall survive expiration or termination of this AGREEMENT.

 

	8.2	Insurance.

 

		(a)	Beginning at such time as
any such product, process or service is being commercially distributed, sold, leased or
otherwise transferred, or performed or used (other
than for the purpose of obtaining regulatory approvals),
by COMPANY, an AFFILIATE or SUBLICENSEE, COMPANY shall, at its sole cost and expense, procure and maintain commercial general liability
insurance in amounts not less than [***] per incident and [***] annual aggregate and naming the INDEMNITEES
as additional insureds. Such commercial general liability insurance shall provide (i) product
liability coverage and (ii) broad form contractual liability coverage for COMPANY's indemnification
under Section 8.1 of this AGREEMENT. If COMPANY elects to self-insure all or
part of the limits described above (including deductibles or retentions which are in excess
of $250,000 annual aggregate) such self-insurance program must be acceptable to HOSPITAL and
the Risk Management Foundation. The minimum amounts of insurance coverage required under this Section 8.2 shall not be construed to create
a limit of COMPANY's liability with respect to its indemnification under Section 8.1 of this
AGREEMENT.

  

		(b)	COMPANY shall
provide HOSPITAL with written evidence of such insurance upon request of
HOSPITAL. COMPANY shall provide HOSPITAL with written notice at least fifteen (15) days prior to the cancellation, non-renewal
or material change in such insurance; if COMP ANY does
not obtain replacement insurance providing comparable coverage prior to the expiration
of such fifteen (15) day period, HOSPITAL shall
have the right to terminate this AGREEMENT effective at the
end of such
fifteen (15) day
period without notice
or any additional
waiting periods.

 

		(c)	COMPANY
                                            shall maintain such commercial general liability insurance beyond the expiration or termination
                                            of this AGREEMENT during (i) the period that any such product, process, or service is being
                                            commercially distributed, sold, leased or otherwise transferred, or performed or used (other
                                            than for the purpose of obtaining regulatory approvals), by COMPANY or by a SUBLICENSEE,
                                            AFFILATE or agent of COMPANY and (ii) a reasonable period after the period referred to in (c) (i) above which in no event shall be less than [***]. 

  

    18 

     

    

  

		(d)	This
                                         section 8.2 shall survive expiration of termination of this AGREEMENT.

 

9.
TITLE; DISCLAIMER OF WARRANTIES; LIMITATION OF LIABILITIES

 

9.1          Title
to PATENT RIGHTS. To the best knowledge of HOSPITAL’s Office of Corporate Sponsored Research and Licensing, HOSPITAL and
BIDMC are the owners by assignment of the PATENT RIGHTS ([***] is co-owner of BWH Case [***]). HOSPITAL has the authority to enter into
this AGREEMENT and license the PATENT RIGHTS to COMPANY hereunder.

 

9.2         
Disclaimer of Warranties. EXCEPT AS MAY BE EXPRESSLY SET FORTH HEREIN, HOSPITAL MAKES NO REPRESENTATIONS OR WARRANTIES
OF ANY KIND CONCERNING THE PATENT RIGHTS AND THE RIGHTS GRANTED HEREUNDER, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF PATENT RIGHTS CLAIMS, WHETHER ISSUED OR PENDING, AND THE ABSENCE
OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, AND HEREBY DISCLAIMS THE SAME. SPECIFICALLY, AND NOT TO LIMIT THE FOREGOING,
HOSPITAL MAKES NO WARRANTY OR REPRESENTATION (i) REGARDING THE VALIDITY OR SCOPE OF ANY OF THE CLAIM(S), WHETHER ISSUED OR PENDING,
OF ANY OF THE PATENT RIGHTS, AND (ii) THAT THE EXPLOITATION OF THE PATENT RIGHTS OR ANY PRODUCT WILL NOT INFRINGE ANY PATENTS
OR OTHER INTELLECTUAL PROPERTY RIGHTS OF HOSPITAL, BIDMC OR OF ANY THIRD PARTY.

 

9.3         Limitation
of Liability. IN NO EVENT SHALL HOSPITAL, BIDMC OR ANY OF THEIR AFFILIATES OR ANY OF THEIR RESPECTIVE TRUSTEES,
DIRECTORS, OFFICERS, MEDICAL AND PROFESSIONAL STAFF, EMPLOYEES AND AGENTS BE LIABLE TO LICENSEE OR ANY OF ITS AFFILIATES,
SUBLICENSEES OR DISTRIBUTORS FOR INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY KIND ARISING IN ANY
WAY OUT OF THIS AGREEMENT OR THE LICENSE RIGHTS GRANTED HEREUNDER, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, INCLUDING
WITHOUT LIMITATION ECONOMIC DAMAGES OR INJURY TO PROPERTY OR LOST PROFITS, REGARDLESS OF WHETHER HOSPITAL OR BIDMC SHALL BE
ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING.

 

10.
TERM AND TERMINATION

 

10.1       Term. The
term of this AGREEMENT shall commence on the
EFFECTIVE DATE and shall remain in effect until the later of the following: (a) the date on
which all issued patents and filed patent applications within the PATENT RIGHTS have expired or been abandoned, (b) one (I)
year after the last COMMERCIAL SALE for which a royalty is due under Section 4.7(a)(ii), or (c) ten (10) years from the date of the
FIRST COMMERCIAL SALE; unless this AGREEMENT is terminated earlier in accordance with a separate provision under this Article
10.

 

    19 

     

    

 

10.2       Termination
for Failure to Pay. If COMPANY fails to make any payment due hereunder, HOSPITAL shall have the right to terminate this AGREEMENT
upon ten (I 0) business days written notice, unless COMPANY makes such payments plus any interest due, as set forth in Section 4.11,
within said ten (I 0) day notice period. If payments are not made, HOSPITAL may immediately terminate this AGREEMENT at the end of said
ten (I 0) day period. COMPANY shall be entitled to only one such cure period in a calendar year; for a second failure to make payment
on time, HOSPITAL shall have the right to terminate this AGREEMENT immediately upon written notice.

 

10.3       Termination
for Insurance and Insolvency. HOSPITAL shall terminate this AGREEMENT immediately upon written notice with no further notice obligation
or opportunity to cure if COMPANY fails to maintain the insurance required by Section 8.2 or if COMPANY shall become insolvent, shall
make an assignment for the benefit of creditors, or shall have a petition in bankruptcy filed for or against it.

 

I
0.4Termination for Non-Financial Default. If COMPANY, its AFFILIATES or SUBLICENSEES shall default in the performance of any
of its obligations under this AGREEMENT, including but not limited to its obligations under Section 3.l(a)(i-vi) or Section 3.l(b)(i),
and if such default has not been cured within sixty (60) days after notice by HOSPITAL in writing of such default, HOSPITAL may immediately
terminate any licenses granted hereunder with respect to the country or countries in which such default has occurred at the end of said
sixty (60) day cure period. HOSPITAL shall also have the right to terminate such licenses immediately, upon written notice, in the event
of repeated defaults even if cured within such sixty (60) day periods.

 

10.5       Termination
by Company. COMPANY shall have the right to terminate this AGREEMENT by giving ninety (90) days advance written notice to HOSPITAL
and upon such termination shall immediately cease all use and TRANSFER of PRODUCTS and PROCESSES.

 

I
0.6Effect of Termination on Sublicenses. Any sublicenses granted by COMPANY under this AGREEMENT shall provide for termination
or assignment to HOSPITAL of COMPANY's interest therein, at the option of HOSPITAL, upon termination of this AGREEMENT or upon termination
of any license hereunder under which such sublicense has been granted.

 

10.7       Effects
of Termination of AGREEMENT. Upon termination of this AGREEMENT or any of the licenses hereunder for any reason, final reports in
accordance with Article 5 shall be submitted to HOSPITAL and all royalties and other payments, including without limitation any unreimbursed
PATENT COSTS, accrued or due to HOSPITAL as of the termination date shall become immediately payable. COMPANY shall cease, and shall
cause its AFFILIATES and SUBLICENSEES to cease under any sublicense granted by COMPANY, all TRANSFERS and uses of PRODUCTS and PROCESSES
upon such termination. The termination or expiration of this AGREEMENT or any licenses granted hereunder shall not relieve COMPANY, its
AFFILIATES or SUBLICENSEES of obligations arising before such termination or expiration.

 

    20 

     

    

 

 

11.
COMPLIANCE WITH LAW

 

11.1
       Compliance. COMPANY shall have the sole obligation for compliance with and
shall ensure that any AFFILIATES and SUBLICENSEES comply with, all government statutes and regulations that relate to
PRODUCTS and PROCESSES, including, but not limited to, FDA statutes and regulations and the Export Administration Act of
1997, as amended, and the regulations promulgated thereunder, and any applicable similar laws and regulations of any other
country in the LICENSE TERRITORY.

 

11.2       Patent
Numbers. COMPANY shall cause all PRODUCTS sold in the United States to be marked with all applicable U.S. Patent Numbers,
to the full extent required by United States law. COMPANY shall similarly cause all PRODUCTS shipped to or sold in any other country
to be marked in such a manner as to conform with the patent laws and practices of such country.

 

12.
MISCELLANEOUS

 

12.1      
Entire Agreement. This AGREEMENT constitutes the entire understanding between the PARTIES with respect to the subject matter
hereof.

 

12.2      
Notices. Any written notices, reports, waivers, correspondences or other communications required under or pertaining to
this AGREEMENT, and including all payments required hereunder, shall be given by prepaid, first class, registered or certified
mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other PARTY, as follows:

 

If
to COMPANY:

 

[***]

 

If
to HOSPITAL:

 

[***]

 

    21 

     

    

 

Notices
and payments shall be considered timely if such notices are received on or before the established deadline date or sent on or
before the deadline date as verifiable by legibly dated U.S. Postal Service postmark or dated receipt from a commercial carrier.

 

12.3        Amendment;
Waiver. This AGREEMENT may be amended and any of its terms or conditions may be waived only by a written
instrument executed by an authorized signatory of the PARTIES or, in the case of a waiver, by the PARTY waiving compliance.
The failure of either PARTY at any time or times to require performance of any provision hereof shall in no manner affect its
rights at a later time to enforce the same. No waiver by either PARTY of any condition or term shall be deemed as a further
or continuing waiver of such condition or term or of any other condition or term.

 

12.4       Binding
Effect. This AGREEMENT shall be binding upon and inure to the benefit of and be enforceable by the PARTIES hereto and
their respective permitted successors and assigns.

 

	12.5     
                                            Assignment. Except as set forth in this Section 12.5 and Section 12.6, COMPANY shall
                                            not assign any of its rights or obligations under this AGREEMENT without the prior written
                                            consent of HOSPITAL. Provided COMPANY has fulfilled its diligence obligations as set forth
                                            in Article 3, no such consent will be required
                                            to assign this AGREEMENT to a successor of COMPANY's
                                            business to which this AGREEMENT pertains or
                                            to a purchaser of substantially all of COMPANY's
                                            assets related to
                                            this AGREEMENT, so long as such successor or purchaser shall agree in
                                            writing to be bound by the terms
                                            and conditions here of prior to such assignment. COMPANY shall notify HOSPITAL in
                                            writing of any such assignment and provide a
                                            copy of all assignment documents and related agreements to HOSPITAL
                                            within thirty (30) days of such assignment. Failure of an assignee to agree to be
                                            bound by the terms hereof or
                                            failure of COMPANY to notify HOSPITAL
                                            and provide copies of assignment documentation shall
                                            be grounds for termination of this AGREEMENT for default.

 

12.6       The
PURCHASE AGREEMENT. Subject to the terms of this Section 12.6, HOSPITAL
acknowledges and agrees that (a) COMPANY has granted a security interest in this
AGREEMENT to KLP pursuant to the PURCHASE AGREEMENT; (b) KLP may sell, assign and
otherwise transfer this AGREEMENT in exercising its right as a secured party upon a
default by COMPANY under the PURCHASE AGREEMENT or any other instrument, document or
agreement; and (c) KLP may exercise any and all other rights it may have as a secured
party with respect to this AGREEMENT under the
Connecticut Uniform Commercial Code ("UCC"). Any transferee of this AGREEMENT
("TRANSFEREE") must (i) promptly cure any default of COMPANY under this AGREEMENT,
including the payment of any extension fees due under Section 3.2, (ii) pay the assignment fee set forth in Section 4.9 and (iii)
agree in writing to be bound by the terms and conditions of this AGREEMENT. KLP shall notify HOSPITAL of
any default of COMPANY under the PURCHASE AGREEMENT or related instruments, documents or agreements within (30) day of such default.
KLP must exercise any right to sell, assign or otherwise transfer this AGREEMENT, as set forth above, within one (I) year of the
date it exercises any remedy as a secured party under the PURCHASE AGREEMENT or UCC. Any transfer of this AGREEMENT by KLP to a
TRANSFEREE shall be subject to the prior written approval of HOSPITAL, which approval shall not be unreasonably withheld or delayed.
Failure of any TRANSFEREE to agree to be bound by the terms of this AGREEMEENT shall be grounds for termination of this AGREEMENT
for default.

  

    22 

     

    

 

12.7       
Force Majeure. Neither PARTY shall be responsible for delays resulting from causes beyond the reasonable control of such
PARTY, including without limitation fire, explosion, flood, war, sabotage, strike or riot, provided that the nonperforming PARTY
uses commercially reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this AGREEMENT
with reasonable dispatch whenever such causes are removed.

 

12.8       
Use of Name. Neither PARTY shall use the name of the other PARTY or of any trustee, director, officer, staff member, employee,
student or agent of the other PARTY or any adaptation thereof in any advertising, promotional or sales literature, publicity or
in any document employed to obtain funds or financing without the prior written approval of the PARTY or individual whose name
is to be used. For HOSPITAL, such approval shall be obtained from HOSPITAL’s Chief Public Affairs Officer. COMPANY may use
HOSPITAL’s name where appropriate for investor due diligence purposes in any financing undertaken by COMPANY.

 

12.9       
Governing Law. This AGREEMENT shall be governed by and construed and interpreted in accordance with the laws of the Commonwealth
of Massachusetts, except that questions affecting the construction and effect of any patent shall be determined by the law of
the country in which the patent shall have been granted. Each PARTY agrees to submit to the exclusive jurisdiction of the Superior
Court for Suffolk County, Massachusetts, and the United States District Court for the District of Massachusetts with respect to
any claim, suit or action in law or equity arising in any way out of this AGREEMENT or the subject matter hereof.

 

12.10     
Hospital Policies. COMPANY acknowledges that HOSPITAL’s employees and medical and professional staff members and
the employees and staff members of HOSPITAL’s AFFILIATES are subject to the applicable policies of HOSPITAL and such AFFILIATES,
including, without limitation, policies regarding conflicts of interest, intellectual property and other matters. COMPANY shall
provide HOSPITAL with any agreement it proposes to enter into with any employee or staff member of HOSPITAL or any of HOSPITAL’s
AFFILIATES for HOSPITAL’s prior review and shall not enter into any oral or written agreement with such employee or staff
member which conflicts with any such policy. HOSPITAL shall provide COMPANY, at
COMPANY’s request,
with copies of any such policies applicable to any such employee or staff member.

  

    23 

     

    

 

12.11     
Severability. If
any provision(s) of this AGREEMENT are or become invalid, are ruled illegal by any court of competent jurisdiction or are deemed
unenforceable under then current applicable law from time to time in effect during the term hereof, it is the intention of the
parties that the remainder of this agreement shall not be affected thereby. It is further the intention of the parties that in
lieu of each such provision which is invalid,
illegal or unenforceable,
there be substituted or added
as part of this AGREEMENT a provision which shall be as similar as possible in economic and business objectives as intended by
the parties to such invalid,
illegal or enforceable provision,
but shall be valid,
legal and enforceable.

 

12.12     
Survival. In addition to any specific survival references in this AGREEMENT,
Sections 1,
2.4, 5.5, 8.1, 8.2,
9.1,
9.2,
9.3, 10.6 ,
10.7,
12.2,
12.7,
12.8,
12.9, 12.10, 12.11,
12:12, 12.13 and 12.14 shall
survive termination or expiration
of this AGREEMENT.

 

12.13     
Interpretation. The parties hereto
are sophisticated, have had the opportunity to consult legal counsel with respect to this transaction and hereby waive any presumptions
of any statutory or common law rule relating to the interpretation of contracts against the drafter .

 

12.14     
Headings. All
headings are for convenience only and shall not affect the meaning of any provision of this AGREEMENT.

 

[Remainder
of page intentionally left blank.]

  

    24 

     

    

IN
WITNESS WHEREOF, the PARTIES have caused this AGREEMENT to be executed by their duly authorized representatives
as of the date first written above.

 

	 	Alopexx
    Pharmaceuticals LLC	 	 	The
    BRIGHAM AND WOMEN’S HOSPITAL, INC
	 	 	 	 	 
	By
	/s/
                                         Daniel Vlock
	 
	By
	/s/
                                         Vendana Desai Yajnik, PhD

	Name:
    	Daniel Vlock	 	Name: 	Vendana Desai Yajnik, PhD
	Title	CEO	 	Title	Associate
Director Corporate Sponsored Research & Licensing 

	Date	December
    4, 2007	 	Date	December
    5, 2007

 

    25 

     

    

 

Appendix
A

 

Interinstitutional
Agreement between HOSPITAL and [***]

  

    26 

     

    

 

Appendix
B

 

BIOLOGICAL
MATERIALS

 

[***]

  

    27 

     

    

 

Appendix
C

 

PATENT
RIGHTS

 

[***]

  

    28 

     

    

 

Appendix
D

 

PURCHASE
AGREEMENT

 

[***]

  

    29 

     

    

 

Appendix
E

 

COMMERCIAL
SALES REPORTS

 

(see
attached)

  

    30 

     

    

 

	AGREEMENT INCOME REPORT 	Non-royalty
    Income

 

BWH
Agreement# -   A10100                   
Licensee -  ___________ Sub-Licensee - ___________

 

Separate
reports must be filed for Payments associated with each Product:

 

	Product
                            Name:	

 

 

Report
Time Period:

 

	 	From	mm/dd/yyyy	 
    
	 	To	mm/dd/yyyy	 
    

  

	 	 	 	 
	 	Detailed
    Explanation of Payment
	 	Required
    for “Other Payment”
	Annual
    Fees	$	 
    	 	 
	Milestone
    Payments	$	 
    	 	 
	Sublicense
    Fees and Royalties	$	 
    	 	 
	Other
    Payment	$	 
    	 	 
	Other
    Payment	$	 
    	 	 
	Other
    Payment	$	 
    	 	 
	TOTAL	$		 	 
	 	 	 	 	 
	 	 	 	 	 

 

PLEASE
ATTACH DETAIL AS REQUIRED

  

    31 

     

    

 

	AGREEMENT INCOME REPORT 	Royalty
    Income

 

BWH
Agreement# - A10100

	Licensee -	

	Sub-Licensee
-	

 

Separate
reports must be filed for:

		1.	Each
                                         Product sold.

		2.	Each
                                         country of sale, if different deductions or royalty rates apply.

 

	Product
                            Name:	

  

Report
Time Period:

 

	 	From	mm/dd/yyyy	 
    
	 	To	mm/dd/yyyy	 
    

 

 

 

 

 

	Country
    of Sale		 		 	
	 	 	 	 	 	 
	Quantity
    Sold	 	 	 	 	 
	 	 	 	 	 	 
	Gross
    Sales (USD 	$
                                         
	 	$
                                          
	 	$
       
	 	 	 	 	 	 
	Exchange
    Rate	 	 	 	 	 

 

Deductions
and Credits (Itemize) 

Please
list each deduction and credit separately. 

Use
same definition as appears in agreement and include the contract paragraph as a reference.

 

	1.
    	 
    	 	 
    	 	 
	2.
    	 
    	 	 
    	 	 
	3.
    	 
    	 	 
    	 	 
	4.
    	 
    	 	 
    	 	 

 

	Net
    Sales		 		 	
	 	 	 	 	 	 
	Royalty
    Percentage	 	 	 	 	 
	 	 	 	 	 	 
	Royalty
    Due 	$
                                         
	 	$
                                          
	 	$
       
	 	 	 	 	 	 
	 	 	 	 	 	 

 

PLEASE
ATTACH DETAIL SALES REPORTS AS REQUIRED

 

 

    32 

     

    

 

 

 

[***] Certain information in this document has been excluded pursuant
to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm if publicly disclosed

 

AMENDMENT No. 1 to 

EXCLUSIVE LICENSE AGREEMENT

 

BWH Case Nos [***], [***], [***]

Agreement No. [***]

 

THIS Amendment No. 1 to the License Agreement (as
defined below) (“Amendment”) is effective as of the “Amendment Effective Date”(defined below), by and between
The Brigham and Women’s Hospital, Inc., a not-for-profit corporation, having a primary place of business at 75 Francis Street, Boston,
Massachusetts 02115 (“BWH”) and Alopexx Pharmaceuticals, LLC, a Delaware limited liability company, having a principal place
of business at [***] (“COMPANY”) (each individually a “PARTY” and together collectively the “PARTIES”).

 

BACKGROUND

 

WHEREAS, BWH and COMPANIES are parties to an exclusive
license agreement ([***]) which has an effective date of December 4, 2007 (the “License Agreement”); and

 

WHEREAS, COMPANY is [***]

 

WHEREAS, the PARTIES would like to [***];

 

Except as expressly modified hereby, the terms of
the License Agreement remain in full force and effect and shall govern and apply to this Amendment. Unless otherwise indicated, all defined
terms shall have the same meaning in this Amendment as in the License Agreement.

 

NOW THEREFORE, in consideration of the covenants and
undertakings hereinafter set forth, it is agreed by and between the parties as follows:

 

	 	1.	Section 1.3 of the License Agreement shall be deleted and replaced with the following:

 

“1.3 “CLAIM” shall mean any issued claim of
any PATENT RIGHT in a country, that has not been permanently revoked, nor held unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction that is unappealable or unappealed in the time allowed for appeal, and which has not been
admitted to be invalid or unenforceable through reissue or disclaimer or otherwise in such country.” 

 

     

     

     

 

	 	2.	Section 1.4 of the License Agreement shall be deleted and replaced with the following:

 

 

“COMMERCIAL SALE” shall mean any TRANSFER of a PRODUCT
or PROCESS by COMPANY, an AFFILIATE, SUBLICENSEE or SUBSEQUENT SUBLICENSEE (which may include a TRANSFER to an AFFILIATE, SUBLICENSEE,
or SUBSEQUENT SUBLICENSEE), for value, in the form of cash or otherwise.”

 

	 	3.	Section 1.9 of the License Agreement shall be deleted and replaced with the following:

 

	 	“1.9	“NET SALES” shall mean:

 

The amount invoiced or otherwise billed by
COMPANY, its AFFILIATE, SUBLICENSEES or SUBSEQUENT SUBLICENSEES [***].

 

A sale of a PRODUCT is deemed
to occur upon invoicing [***]

 

[***].

 

    2 

     

     

[***].

 

[***]

 

	 	4.	The following provisions shall be added to Article 1 of the License Agreement:

 

“1.18      SUBSEQUENT SUBLICENSEE
shall mean a third party sublicense of the rights granted by a SUBLICENSEE in accordance with [***].

 

1.19        SUBSEQUENT
SUBLICENSE shall mean a sublicense granted by a SUBLICENSEE in accordance with [***].”

 

	 	5.	Section [***] of the License
    Agreement shall be deleted and replaced with the following:

 

“2.2 All sublicenses granted hereunder
shall be consistent with the terms of this AGREEMENT, to the extent that such sublicenses shall incorporate terms and conditions sufficient
to enable COMPANY to comply with this AGREEMENT. [***]

 

Under approved sublicenses, the right of
SUBLICENSEES to grant “SUBSEQUENT SUBLICENSES” shall be subject to the following restrictions and conditions:

 

	 	(i)	[***].

 

	 	(ii)	[***].

 

	 	(iii)	[***].

 

	 	(iv)	[***].

 

	 	(v)	[***]

 

	 	(vi)	[***].

 

    3 

     

     

	 	(vii)	[***].

 

	 	(viii)	[***]

 

	 	(ix)	[***]

 

	 	6.	[***] of the License Agreement shall be deleted and replaced with the following:

 

[***]

 

	 	7.	Section [***].

 

	 	8.	The following provision shall be added to the end of Section 3.1(a):

 

[***]

 

	 	9.	Section [***]:

 

“Audit Rights. COMPANY shall
maintain, and shall cause each of its AFFILIATES and SUBLICENSEES to maintain, complete and accurate records relating to the rights and
obligations under this AGREEMENT and any amounts payable to HOSPITAL in relation to this AGREEMENT, which records shall contain sufficient
information to permit HOSPITAL and its representatives to confirm the accuracy of any payments and reports delivered to HOSPITAL and compliance
in all other respects with this AGREEMENT. COMPANY shall retain and make available, and shall cause each of its AFFILIATES and SUBLICENSEES
to retain and make available, such records for at least three (3) years following the end of the calendar year to which they pertain,
to HOSPITAL and/or its representatives, at HOSPITAL’s expense and upon at least fifteen (15) days’ advance written notice,
for inspection during normal business hours, to verify any reports and payments made and/or compliance in other respects under this AGREEMENT.
If any examination conducted by HOSPITAL or its representatives pursuant to the provisions of this Section show an underreporting or underpayment
of five percent (5%) or more in any payment due to HOSPITAL hereunder, COMPANY shall bear the full cost of such audit and shall remit
any amounts due to HOSPITAL (including interest due in accordance with Section 4.11) within thirty (30) days of receiving notice thereof
from HOSPITAL. If such examination shows any overpayment of five percent (5%) or more in any payment due HOSPITAL, HOSPITAL shall remit
the overpayment amount to COMPANY within thirty (30) days of the determination of an overpayment.”

 

    4 

     

      

	 	10.	Section 7.1 of the License Agreement shall be deleted and replaced with the following:

 

“Enforcement of Patent
Rights, Defense of Infringement Actions. COMPANY and HOSPITAL each promptly, but in any event no later than [***] after receipt of
notice or after becoming aware of an action, shall notify the other in writing of any patent nullity actions, any declaratory
judgment actions or any alleged or threatened invalidity or unenforceability infringement of PATENT RIGHTS, or if either PARTY, or
any of their respective Affiliates, shall be individually named as a defendant in a legal proceeding by a Third Party alleging
infringement of PATENT RIGHTS arising from this AGREEMENT.”

 

	 	11.	Section 7.2 of the License Agreement shall be deleted and replaced with the following:

 

[***]

 

	 	12.	Section 7.4 of the License Agreement shall be deleted and replaced with the following:

 

[***]

 

	 	13.	Section 7.6 of the License Agreement shall be deleted and replaced with the following:

 

“7.6 [***]:

 

	 	(i)	[***].

 

	 	(i)	[***]

 

	 	14.	Section [***] of the License
    Agreement shall be deleted and replaced with the following:

 

[***]

 

	 	15.	Section of the License Agreement shall be deleted and replaced with the following:

 

“12.5 [***] 

 

    5 

     

     

 

16.          A
new section 9.2 shall be introduced as follows as part of Article 9 which shall be titled as “Representations and Warranties, Disclaimer
and Limitation of Liabilities” and Section 9.2 and 9.3 shall be renumbered 9.3 and 9.4 respectively: 

 

	 	“9.2	Additional Representations
    and Warranties of HOSPITAL [***]

 

	 	(i)	[***].

 

	 	(ii)	[***].

 

	 	(iii)	[***].

 

	 	(iv)	[***]

 

	 	17.	Sections 4.5(d) and 4.5(e) shall be [***].

 

This Amendment shall be effective as of effective
date of the Sublicense Agreement (the “Amendment Effective Date”), and this Amendment shall automatically expire upon the
termination of the Sublicense Agreement. Nothing in this Amendment shall be construed as amending or modifying by implication or otherwise
any of the rights or obligations provided in the License Agreement, except as expressly set forth in this Amendment.

 

[The remainder of this page
is left intentionally blank]

 

    6 

     

     

IN WITNESS WHEREOF, the parties hereto have duly executed
and delivered this Amendment to be effective as of the date hereof.

 

 

	THE BRIGHAM AND WOMEN’S HOSPITAL, INC.	 	ALOPEXX PHARMACEUTICALS, LLC
	 	 	 	 	 
	By:	/s/ Brian N Hicks	 	By:	/s/  Daniel R. Vlock
	 	 	 	 	 
	Title:	Executive Director	 	Title:	CEO
	 	 	 	 	 
	Name:	 	 	Name:	Daniel R. Vlock, M.D.
	 	 	 	 	 
	Date:	30 Nov 2009	 	Date:	November 30, 2009

   

    7 

     

    

 

 

 

[***] Certain information in this document has
been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive
harm if publicly disclosed

 

AMENDMENT No. 2 to 

EXCLUSIVE LICENSE AGREEMENT

 

BWH Case Nos [***], [***], [***]

 

Agreement No. [***]

 

THIS Amendment No. 2 to the License
Agreement (as defined below) (“Amendment 2”) is effective as of the “Amendment Effective Date” (defined below),
by and between The Brigham and Women’s Hospital, Inc., a not-for-profit corporation, having a primary place of business at 75 Francis
Street, Boston, Massachusetts 02115 (“BWH”) and Alopexx Pharmaceuticals, LLC, a Delaware limited liability company, having
a principal place of business at [***] (“COMPANY”) (each individually a “PARTY” and together collectively the “PARTIES”).

 

WHEREAS, BWH and COMPANY are parties
to an exclusive license agreement ([***]) which has an effective date of December 4, 2007, as amended on December 3, 2009 ([***]) (collectively,
the “License Agreement”), and;

 

WHEREAS, COMPANY has [***]

 

WHEREAS, the PARTIES would like to further amend the
License Agreement;

 

IT IS AGREED by the PARTIES that
except as expressly modified hereby, the terms of the License Agreement remain in full force and effect and shall govern and apply to
this Amendment 2. Unless otherwise indicated, all defined terms shall have the same meaning in this Amendment 2 as in the License Agreement.

 

NOW THEREFORE, in consideration of the covenants and
undertakings hereinafter set forth, it is agreed by and between the PARTIES as follows:

 

	 	1.	Sections [***] of the License Agreement shall be [***].

 

	 	2.	Brigham shall [***].

 

     

     

     

	 	3.	The instructions for payment in Section 4.10 of the License Agreement shall be revised such that the last paragraph is replaced with the following information:

 

“Payments by check should be addressed to:

[***]

Payments via wire transfer should be made as follows: 

[***]

 

	 	3.	This Amendment 2 shall be effective as of December 3, 2009 (“Amendment 2 Effective Date), and this Amendment 2 shall automatically expire upon the termination of the Sublicense Agreement. Nothing in this Amendment 2 shall be construed as amending or modifying by implication or otherwise any of the rights or obligations provided in the License Agreement, except as expressly set forth in this Amendment 2.

 

IN WITNESS WHEREOF, the PARTIES hereto have duly executed
and delivered this Amendment 2 to be effective as of the Amendment 2 Effective Date.

 

 

	THE BRIGHAM AND WOMEN’S HOSPITAL, INC.	 	ALOPEXX PHARMACEUTICALS, LLC
	 	 	 	 	 
	By:	/s/ Yogesh Sharma, PhD, MBA	 	By:	 /s/  Daniel R. Vlock 
	 	 	 	 	 
	Title:	Associate Director Innovation	 	Title:	CEO
	 	 	 	 	 
	Name:	Yogesh Sharma, PhD, MBA	 	Name:	Daniel R. Vlock, M.D.
	 	 	 	 	 
	Date:	27 Jan 2010	 	Date:	January 27, 2010

  

    2 

     

    

 

 

[***] Certain information
in this document has been excluded pursuant to Regulation S -K, Item 601(b)(10). Such excluded information is not material and would likely
cause competitive harm if publicly disclosed

 

AMENDMENT No. 3 to 

EXCLUSIVE LICENSE AGREEMENT 

 

BWH Case Nos [***], [***], [***], [***]

 

Agreement No. [***]

 

THIS Amendment No. 3 to the License
Agreement (as defined below) (“Amendment No. 3”) is effective as of the “Amendment Effective Date” (defined below),
by and between The Brigham and Women’s Hospital, Inc., a not-for-profit corporation, having a primary place of business at 75 Francis
Street, Boston, Massachusetts 02115 (“BWH”) and Alopexx Pharmaceuticals, LLC, a Delaware limited liability company, having
a principal place of business at [***] (“COMPANY”) (each individually a “PARTY” and together collectively the “PARTIES”).

 

BACKGROUND

 

WHEREAS, BWH and COMPANY are parties to an
exclusive license agreement (BWH# [***]) which has an effective date of December 4, 2007, as amended on December 3, 2009 (BWH# [***];
BWH [***]) (collectively, the “License Agreement”); and

 

WHEREAS, COMPANY entered into a certain sublicense
agreement (BWH# [***]) with [***] having its principal place of business at [***], for a sublicense of the rights granted to Alopexx under the
License Agreement, and having an effective date of December 3, 2009 (the “Sublicense Agreement”); and

 

WHEREAS, BWH and COMPANY executed two amendments to
the License Agreement, Amendment and Amendment 2 (collectively, the “Amendments”), having an effective date of December 3,
2009, in order to amend the License Agreement to accommodate certain negotiated terms of the Sublicense Agreement; and

 

WHEREAS, [***] subsequently [***].

 

WHEREAS, the PARTIES would like to further amend the
License Agreement in order to accommodate the [***]; and

 

WHEREAS, COMPANY has made a request [***]; and

 

WHEREAS, the PARTIES would like to further amend the
License Agreement to modify the PATENT RIGHTS to include BWH [***].

 

     

     

     

Except as expressly modified hereby, the terms of
the License Agreement remain in full force and effect and shall govern and apply to this Amendment 3. Unless otherwise indicated, all
defined terms shall have the same meaning in this Amendment 3 as in the License Agreement.

 

NOW THEREFORE, in consideration of the covenants and
undertakings hereinafter set forth, it is agreed by and between the PARTIES as follows:

 

1. The Parties are in agreement that [***]

 

2. Section 1.10 of the License Agreement shall be
deleted and replaced with the following:

 

1.10 “PATENT
RIGHTS” shall mean HOSPITAL’s rights and [***] in (a) patents and patent applications listed on ***attached hereto;
(b) any divisions, continuations, continuations-in-part to the extent the claims are supported by the patent applications and
patents included in (a), reissues, reexaminations or extensions of the patent applications and patents in (a); (c) any foreign
counterparts and equivalents of the patent applications and patents listed in (a) and (b); and (cl) all patents issuing therefrom
anywhere in the world. For clarity the PATIENT RIGHTS are [***]. BWH [***] is [***]. BWH Cases [***], [***], and [***] are [***].

 

3, Section 3.1 of the License Agreement shall be deleted
and replaced with the following:

 

3.1           Diligence
Requirements. COMPANY shall itself use, or shall cause its AFFILIATES or SUBLICENSEES, as applicable, to use, best cffo1ts to develop
and make available to the public PRODUCTS and PROCESSES throughout the LICENSE TERRITORY in the LICENSE FIELD. Such efforts shall include
achieving the following objectives within the time periods designated below following the EFFECTIVE DATE:

 

(a) Pre-Sales Requirements.

 

	 	(i)	Within [***] of the
    EFFECTIVE DATE and [***] thereafter as set forth in Section [***], COMPANY shall [***];

 

	 	(ii)	Within [***], COMPANY will [***]. Acceptable documentation will be [***];

 

     2

     

    	 	(iii)	Within [***] COMPANY will c[***];

 

	 	(iv)	Within [***] COMPANY will [***];

 

	 	(v)	Within [***] COMPANY will [***]; and

 

	 	(vi)	Within [***] COMPANY will
    [***].

 

	 	4.	Section 4.2 of the License Agreement shall be deleted and replaced with the following:

 

4.2
Patent Cost Reimbursement for BWH Case [***] and Case [***]

 

	 	(a)	COMPANY shall [***]:

 

(i) Payment [***] shall be due upon [***]; 

(ii) Payment in the amount of [***] shall all be due on [***];

(iii) Payment in the amount [***] shall be due on [***];

(iv) Payment in the amount of [***] shall be due on [***];

(v) Payment in the amount of [***] shall be due on [***].

 

COMPANY shall pay HOSPITAL, or at HOSPITAL’s request directly
to patent counsel, all other CASE [***] PATENT COSTS within [***] of COMPANY’s receipt of an invoice for such either from HOSPITAL or
HOSPITAL’s patent counsel. COMPANY agrees to indemnify, defend and hold HOSPITAL [***] harmless from and against any and all liabilities,
damages, costs and expenses arising from the failure of COMPANY to timely pay such invoices and CASE [***] PATENT COSTS. HOSPITAL shall
instruct patent counsel to provide copies to HOSPITAL for HOSPITAL’s administrative files of all invoices detailing CASE [***] PATENT
COSTS which are sent directly to COMPANY.

 

     3

     

     

	 	(b)	COMPANY shall reimburse HOSPITAL for all costs associated with the preparation, filing, prosecution and maintenance of certain PATENT RIGHTS for BWH ***which are directed toward the antibody (“[***]PATENT COSTS”). As of the EFFECTIVE DATE, HOSPITAL has [***] in [***]PATENT COSTS [***] which amount COMPANY [***]:

 

	 	(i)	Payment in the amount of [***] shall be due [***] of COMPANY’s receipt of an invoice for such amount either from HOSPITAL or HOSPITAL’s patent counsel.

 

COMPANY shall pay HOSPITAL, or at HOSPITAL’s request directly
to patent counsel, all other [***]PATENT COSTS within [***] of COMPANY’s receipt of an invoice for such either from HOSPITAL or HOSPITAL’s
patent counsel. COMPANY agrees to indemnify, defend and hold HOSPITAL [***] harmless from and against any and all liabilities, damages,
costs and expenses arising from the failure of COMPANY to timely pay such invoices and ***PATENT COSTS. HOSPITAL shall instruct patent
counsel to provide copies to HOSPITAL for HOSPITAL’s administrative files of all invoices detailing [***] PATENT COSTS which are sent
directly to COMPANY.

 

	 	6.	Section 4.5 of the License Agreement shall be deleted and replaced with the following:

 

	 	4.5	[***]. COMPANY shall [***]occurs:

 

	 	(a)	[***] of the EFFECTIVE DATE: [***];

	 	(b)	[***] of the EFFECTIVE DATE: [***];

	 	(c)	[***] of the EFFECTIVE DATE: [***]; and

	 	(d)	[***] of the EFFECTIVE DATE: [***]; and

	 	(e)	[***] of the EFFECTIVE DATE: [***]; and

	 	(f)	[***] of the EFFECTIVE DATE: [***]; and

 

     4

     

     

	 	(g)	[***] of the EFFECTIVE DATE: [***]

	 	(h)	[***] of the EFFECTIVE DATE: [***] and

	 	(i)	[***] of the EFFECTIVE DATE: [***]; and

	 	(j)	[***] of the EFFECTIVE DATE: [***]; and

	 	(k)	[***] of the EFFECTIVE DATE thereafter:. [***]

 

[***],      

 

	 	7.	Section 4.6 of the License Agreement shall be deleted and replaced with the following:

 

	 	4.6	Milestone Payments. In addition to the payments set forth in [***] , COMPANY shall pay HOSPITAL [***], as follows:

 

(a) [***] within [***]; and

 

(b) [***] within [***]

 

(c) [***] within [***],

 

(d) [***] within [***]

 

	 	8.	Section 6.1 of the License Agreement shall be deleted and replaced with the following:

 

6.1                   Prosecution.
HOSPITAL shall be responsible for the preparation, filing, prosecution and maintenance of all patent applications and patents included
in PATENT RIGHTS. COMPANY shall reimburse HOSPITAL for [***]and [***] PATENT COSTS and its share of GSK PATENT COSTS (hereinafter collectively
referred to as the PATENT COSTS”) incurred by HOSPITAL relating thereto in accordance with [***]. COMPANY shall have the right to
consult with HOSPITAL in the preparation, filing, prosecution and maintenance of patents and patent applications include in PATENT RIGHTS.

 

     5

     

     

 

	 	9.	Appendix C ‘PATENT RIGHTS’ of the License Agreement shall be deleted and replaced with the [***]to this [***].

 

This Amendment 3 shall be effective as of effective
date of the License Agreement (the “Amendment 3 Effective Date”), and this Amendment shall automatically expire upon the termination
of the License Agreement. Nothing in this Amendment 3 shall be construed as amending or modifying by implication or otherwise any of the
rights or obligations provided in the License Agreement, except as expressly set forth in this Amendment 3.

 

[The remainder of this page is left intentionally
blank]

  

     6

     

     

IN WITNESS WHEREOF, the parties hereto have duly executed
and delivered this Amendment to be effective as of the date hereof.

 

 

	THE BRIGHAM AND WOMEN’S HOSPITAL, INC.	 	ALOPEXX PHARMACEUTICALS, LLC
	 	 	 	 	 
	By:	/s/
     Yogesh Sharma	 	By:	 /s/  Daniel R. Vlock
	 	 	 	 	 
	Title:	Associate Director. Innovation	 	Title:	CEO
	 	 	 	 	 
	Name:	Yogesh Sharma, PhD, MBA	 	Name:	Daniel R. Vlock. M.D.
	 	 	 	 	 
	Date:	 	 	Date:	6 March 201

  

     7

     

    

 

 

 

[***] Certain information in this document has been excluded pursuant
to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm if publicly disclosed

 

AMENDMENT No.
4 to

 

EXCLUSIVE LICENSE
AGREEMENT

 

BWH Case No:
[***], [***], and [***]    

 

BWH Agreement
No. [***]

 

This Amendment No. 4 to the Exclusive License Agreement
(“Amendment No. 4”) is effective as of April 29, 2019 (“Amendment No. 4 Effective Date”), by and between The Brigham
and Women’s Hospital, Inc., a not-for-profit Massachusetts corporation, having a primary place of business at 75 Francis Street,
Boston, Massachusetts 02115 (“HOSPITAL”) and Alopexx Pharmaceuticals, LLC, a Delaware limited liability company, having a
principal place of business at [***] (“COMPANY”), each referred to herein individually as a “PARTY” and together
collectively as the “PARTIES”.

 

RECITALS

 

WHEREAS, HOSPITAL and COMPANY have executed
an Exclusive License Agreement which·has an effective date
of December 4, 2007, as amended on December 2, 2009, February 2, 2010 and March 6, 2015 (collectively, the “License Agreement”;
BWH Agreement No. Al 10100);

 

WHEREAS, COMPANY has made a request to amend and restate
the diligence milestones of the License Agreement; and

 

WHEREAS, the PARTIES would like to further amend the PATENT
RIGHTS listed in the License Agreement to remove BWH Case. No. [***].

 

NOW, THEREFORE, for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the PARTIES hereby agree as follows:

 

	 	1.	Certain Definitions. The following terms shall be added to the License Agreement.

 

“NDA”
or “BLA” shall mean either a New Drug Application or Biologics License Application filed with the FDA to obtain Marketing
Approval for a Product in the United States, or any comparable application filed with the applicable Regulatory Authority in or for a
country or jurisdiction other than the United States.

 

“Phase
I Clinical Trial” shall mean a clinical study
of a Product in any country which satisfies the requirements of 21 C.F.R. 312.21(a), as amended from time to time, or its equivalent in
jurisdictions outside of the United States.

 

“Phase II Clinical Trial”
shall mean a clinical study of a Product in any country which satisfies the requirements of 21 C.F.R. 312.21(b), as amended from time
to time, or its equivalent in jurisdictions outside of the United States.

 

“Phase III Clinical
Trial” shall mean a clinical study of a Product in any country which satisfies the requirements of 21 C.F.R. 312.21(c), as amended
from time to time, or its equivalent in jurisdictions outside of the United States.

 

“PMA” shall
mean a Premarket Approval Application of a Product which satisfies the requirements of 21 C.F.R. 814, as amended from time to time.

 

     

     

     

	 	2.	Section 3.1 (a) of the License Agreement (Pre-Sales Requirements) shall be deleted in its entirety and replaced with the following:

 

	 	(a)	Pre-Sales Requirements.

 

	 	(i)	Within [***]after the EFFECTIVE DATE, and annually thereafter as set forth in [***], COMPANY shall [***];

 

	 	(ii)	Within [***]after the EFFECTIVE DATE, COMPANY will [***]

 

	 	(iii)	Within [***]after the EFFECTIVE DATE, COMPANY will [***];

 

	 	(iv)	Within [***]after the EFFECTIVE DATE, COMPANY will [***];

 

	 	(v)	Within [***]after the EFFECTIVE DATE, COMPANY [***]; and

 

	 	(vi)	Within [***]after the EFFECTIVE DATE, COMPANY will [***].

 

	 	3.	The Parties hereby [***] from [***] COMPANY under the License Agreement, including [***]

 

	 	4.	Appendix [***] under the License Agreement is [***]

 

	 	5.	In consideration of this Amendment No. 4, COMPANY shall pay [***] within [***]after the Amendment No. 4 Effective Date and [***]within [***] after the Amendment No. 4 Effective Date.

 

	 	6.	Any capitalized terms not defined in this Amendment No. 4 shall have the meaning set forth in the License Agreement;

 

	 	7.	To the extent the terms of this Amendment No. 4 are contrary to the terms of the License Agreement, the terms of the Amendment No. 4 shall control;

 

     

     

     

	 	8.	Except as specifically amended hereby, all provisions of the License Agreement shall remain in full force and effect;

 

	 	9.	This Amendment No. 4 shall be effective as of the “Amendment No. 4 Effective Date”, and this Amendment No. 4 shall automatically expire upon the termination of the License Agreement. Nothing in this Amendment No. 4 shall be construed as amending or modifying by implication or otherwise any of the rights or obligations provided in the License Agreement, except as expressly set forth in this Amendment No. 4; and

 

	 	10.	For the convenience of the PARTIES, this Amendment No. 4 may be executed electronically by email or facsimile transmission of signature pages, and in counterparts, each of which shall be deemed to be an original, and both of which taken together, shall constitute one agreement binding on both PARTIES. A portable document format (PDF) or electronic copy of this Amendment No. 4, including the signature pages, will be deemed an original.

 

[The remainder
of this page is intentionally left blank.]

 

     

     

     

IN WITNESS WHEREOF, the PARTIES hereto
have duly executed and delivered this Amendment No. 4 to be effective as of the Amendment No. 4 Effective Date as evidenced by the signatures
of their authorized representatives below.

 

	THE BRIGHAM AND WOMEN’S HOSPITAL, INC. 	 	ALOPEXX PHARMACEUTICALS, LLC
	 	 	 	 
	/s/ Daniel Castro	 	By:	/s/ Daniel Vlock
	 	 	 	 
	Name: Daniel Castro	 	Name:	Daniel R Vlock, MD

 

	Title:	 
	 	 
	Date: APRIL 30, 2019	 

 

    	 

     

    

 

[[***]]
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information
is not material and would likely cause competitive harm if publicly disclosed

 

ASSIGNMENT
AND ASSUMPTION AGREEMENT

 

BWH
Case No: [***], [***] and [***]

BWH
Agreement No. [***]

 

This
Assignment and Assumption Agreement (this “Assignment and Assumption Agreement”) is made as of May 3, 2019
(the “ Effective Date”), by and among Alopexx Pharmaceuticals, LLC, a Delaware limited liability company, having
its principal office located at [***] (“Alopexx Pharmaceuticals”), OneBiopharma, Inc., a Delaware corporation
with a business address at [***] (“OneBiopharma”) and the Brigham and Women’s Hospital, Inc. (the “Hospital”).
Each of Alopexx Pharmaceuticals, OneBiopharma and the Hospital is sometimes referred to individually herein as a “Party”
and collectively as the “Parties”.

 

WHEREAS,
Alopexx Pharmaceuticals and Hospital executed an Exclusive License Agreement dated as of December 4, 2007 and amended on December
2, 2009, February 2, 2010, March 6, 2015 and April 30, 2019 (collectively, the “Assigned License Agreement”;
BWH Agreement No. [***]); a copy of which is attached hereto as [***];

 

WHEREAS,
Alopexx Pharmaceuticals desires to assign all of its rights, title and interest in and to the Assigned License Agreement to OneBiopharma;
and

 

WHEREAS,
OneBiopharma desires to accept the assignment of the Assigned License Agreement by Alopexx Pharmaceuticals and assume all of Alopexx
Pharmaceuticals’s liabilities and obligations under the Assigned License Agreement.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby
agree as follows:

 

1.            Assignment
and Assumption of Assigned License Agreement. Alopexx Pharmaceuticals hereby assigns to OneBiopharma all of its existing and
future right, title and interest of every nature in the Assigned License Agreement and OneBiopharma accepts and assumes such Assigned
License Agreement, and hereby assumes, undertakes, and agrees to pay, perform, fulfill and discharge, from and after the Effective
Date, all of Alopexx Pharmaceuticals’s obligations and liabilities under the Assigned License Agreement and agrees to perform
all the terms and conditions of the Assigned License Agreement to be performed by Alopexx Pharmaceuticals on and after the Effective
Date.

 

2.            Hospital
Consent/Knowledge; Assignment fee.

 

(a)            Hospital
hereby consents to (i) the assignment by Alopexx Pharmaceuticals of the Assigned License Agreement, and all of the rights and
obligations of Alopexx Pharmaceuticals in, to and under the Assigned License Agreement, to OneBiopharma, and (ii) the assumption
by OneBiopharma of all of Alopexx Pharmaceuticals’s obligations and liabilities in, to and under the Assigned License Agreement
on and after the Effective Date, all as set forth in this Assignment and Assumption Agreement.

 

     

     

    

		(b)	To
                                         the knowledge of the Hospital’s Innovation Office:

 

		(i)	The
copy of the Assigned License Agreement attached hereto as Exhibit A is a complete, true and accurate copies of the Assigned
License Agreement.

 

		(ii)	The
Assigned License Agreement has not been assigned, amended, modified, supplemented or superseded since its execution other than
as expressly set forth in this Assignment and Assumption Agreement.

 

		(iii)	The
Assigned License Agreement is valid and is in full force and effect.

 

		(iv)	Hospital
has received all payments due and payable by Alopexx Pharmaceuticals under the Assigned License Agreement as of the Effective
Date, including all patent fees and expenses for which it has invoiced Alopexx Pharmaceuticals pursuant to the terms of the Assigned
License Agreement.

 

		(v)	Hospital
has not declared a default under the Assigned License Agreement at any time prior to the date hereof, there are no uncured defaults
on the part of Alopexx Pharmaceuticals under the Assigned License Agreement as of the Effective Date and, as of the Effective
Date, there are no events that have occurred which, with the giving of notice or passage of time or both, would constitute a default
by Alopexx Pharmaceuticals thereunder.

 

		(vi)	The
assignment and assumption of the Assigned License Agreement as set forth herein shall not constitute a sublicense of the Assigned
License Agreement by Alopexx Pharmaceuticals.

 

		(c)	Alopexx
Pharmaceuticals shall [***] of such assignment, as provided under [***] of the Assigned License Agreement. If Alopexx Pharmaceuticals
fails to make payment due hereunder, Hospital shall have the right to revoke this Assignment [***]written notice, unless Alopexx
Pharmaceuticals shall make such payment within [***].

 

3.            Representations
of Alopexx Pharmaceuticals. Alopexx Pharmaceuticals hereby represents to OneBiopharma that:

 

(a)          The
copy of the Assigned License Agreement attached hereto as [***] is a complete, true and accurate copy of the Assigned License Agreement.

 

(b)          The
Assigned License Agreement has not been assigned, amended, modified, supplemented or superseded since its execution other than
as expressly set forth in this Assignment and Assumption Agreement.

 

    2 

     

    

(c)          The
Assigned License Agreement is valid and is in full force and effect.

 

4.            Mutual Representations and Warranties. Alopexx Pharmaceuticals and OneBiopharma each represents and warrants to the other,
as of the Effective Date, as follows:

 

(a)          It is a corporation or limited liability company duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Assignment
and Assumption Agreement.

 

(b)          The execution and delivery of this Assignment and Assumption Agreement and the performance by it of the transactions contemplated
hereby have been duly authorized by all necessary corporate or company action and will not violate (i) such Party’s certificate
of incorporation or bylaws (or equivalent organizational documents), (ii) any agreement, instrument or contractual obligation
to which such Party is bound in any material respect, (iii) any requirement of any applicable laws, or (iv) any order, writ, judgment,
injunction, decree, determination or award of any court or governmental agency presently in effect applicable to such Party. This
Assignment and Assumption Agreement is a legal, valid and binding obligation of such Party, enforceable against it in accordance
with its terms and conditions.

 

5.            Miscellaneous. This Assignment and Assumption Agreement and the rights of the Parties under it shall be governed by and
construed in all respects in accordance with the laws of the Commonwealth of Massachusetts, without regard to its conflicts or
choice of laws rules. This Assignment and Assumption Agreement and the Assigned License Agreement (a) constitute the entire agreement
and understanding between the Parties regarding the Assigned License Agreement, and (b) supersede all prior agreements and understandings,
both written and oral, among the Parties with respect to the Assigned License Agreement. If one or more provisions of this Assignment
and Assumption Agreement shall be held invalid, illegal or unenforceable, such provision shall, to the extent possible, be modified
in such manner as to be valid, legal and enforceable but so as to most nearly retain the intent of the Parties, and if such modification
is not possible, such provision shall be severed from this Assignment and Assumption Agreement and the balance of this Assignment
and Assumption Agreement shall be interpreted as if such provision were so modified or excluded, as the case may be, and shall
be enforceable in accordance with its terms. This Assignment and Assumption Agreement may be executed in any number of counterparts
(including by facsimile and portable document format (PDF) via electronic mail), each such counterpart when executed being deemed
to be an original instrument, and all such counterparts shall together constitute one and the same agreement.

 

[The
remainder of this page is intentionally left blank]

  

    3 

     

    

 

IN WITNESS WHEREOF, the Parties have caused this Assignment and Assumption Agreement to be executed and delivered as a document
under seal as of the Effective Date written above.

 

	ALOPEXX PHARMACEUTICALS, LLC
	 	 	 
	By: 	/s/ Daniel R.
    Vlock                    	 
	Name: Daniel R. Vlock	 
	Title: President and CEO	 

 

[Signature Page to Assignment and Assumption Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the Parties have caused this Assignment and Assumption Agreement to be executed and delivered as a document
under seal as of the Effective Date written above.

 

	ONEBIOPHARMA,
INC.
	 	 	 
	By: 	/s/ Michael Wyand	 
	Name:
Michael Wyand	 
	Title:
Chief Executive Officer	 

 

[Signature Page to Assignment and Assumption Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the Parties have caused this Assignment and Assumption Agreement to be executed and delivered as a document
under seal as of the Effective Date written above. 

 

	THE BRIGHAM AND WOMEN’S HOSPITAL,
    INC.
	 	 	 
	 	/s/ Daniel Castro	 
	Name: 	Daniel Castro	 
	Title: 	Managing Director, Licensing 

Partners HealthCare Innovation	 
	Date:	 	 

 

[Signature Page to Assignment and Assumption Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]